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1 The vitamin theory 
The theory on the existence of nutritional factors essential for human health accompanied 
human history over centuries. Already the ancient Egyptians recognized that night blindness 
– a disease caused by vitamin A deficiency – could be treated by the administration of liver (Al 
Binali 2014). Scurvy, a disease that became most prevalent in sailors between the 15th and 18th 
century, represents another prominent example for a vitamin deficiency disease. The Scottish 
naval surgeon James Lind (1716 - 1794) recognized that scurvy could be treated by the 
consumption of citrus fruits. Nevertheless, it took additional 200 years till the identification of 
vitamin C (Souganidis 2012).  
In 1912, the dietetic factors essential for the treatment of ‘deficiency disorders’, i.e. human 
beriberi, scurvy, rickets and pellagra, were entitled as ‘vitamin’ by the polish scientist Casimir 
Funk (1884 – 1967). The term ‘vitamin’ was a combination of ‘vita’ = life and ‘amine’ = a 
nitrogenous substance essential for life (Piro et al. 2010). The American scientist Elmer 
McCollum (1879-1967) criticized this nomenclature, since the ‘fat-soluble A’ – a substance he 
had recently discovered – did not contain nitrogen. To overcome these discrepancy, the British 
biochemist Sir Jack Cecil Drummond (1891 – 1952) suggested to complement the term 
‘vitamin’ with the letters of the alphabet (Rosenfeld 1997).  
Vitamin research of the early nineteenth century was characterized by slow and stepwise 
progression. Especially animal models enabled the advantage of nutritional research, since 
deficiency experiments generated new insights into the significance of nutrition for health. To 
name a few: Christiaan Eijkman (1858 – 1930) observed that chickens fed with polished rice 
developed polyneuritis, i.e. the equivalent to human beriberi. Eijkman concluded that the 
starch in polished rice carries a toxin that is normally neutralized by the rice bran. Gerrit Grijns 
(1865 – 1944) continued the investigations of Eijkman. He hypothesized that beriberi is caused 
by the lack of a vital nutritional component in the chickens diet, which was later identified as 
vitamin B1 (i.e. thiamin) (Semba 2012). Wilhelm Stepp (1882 – 1964) found that growth of 
young mice was promoted when he provided them a dough made of flour and milk. After he 
extracted the dough with a mixture of alcohol and ether, the mice were only able to survive 
up to three weeks. Interestingly, when the extracted substances were added back to the 
dough, the survival rate of the mice was normalized. Stepp concluded that milk contains a 
substance essential for the survival of mice (vitamin A) (Semba 2012). Although animal studies 
had a significant impact on the progression of vitamin research, it was the isolation and 
chemical synthesis of the vitamins that enabled their detailed characterization. The chemical 
synthesis of vitamins paved the way for modern vitamin research, including the development 
of dietary guidelines, the discovery of vitamin deficiency disorders, the fortification of vitamins 
in foods and the production of vitamin supplements. As an expression of the importance of 
vitamin research for human health, the work of numerous scientist on the field was awarded 
with Nobel Prizes in Chemistry, Physiology or Medicine (Souganidis 2012). 
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2 Vitamin E 
The term vitamin E summarizes a group of lipophilic molecules, which can be classified as 
tocopherols (TOHs), tocotrienols (TEs) and vitamin E related structures. All vitamin E 
molecules consist of a chromanol ring and a covalently connected phytyl-like side chain. Based 
on the saturation of the side chain, the vitamin E molecules are divided into TOHs (bearing a 
saturated side chain) and TEs (carrying an unsaturated side chain). In addition, the methylation 
pattern of the chromanol ring determines the classification as α-, β-, γ- or δ-form of the 
respective TOHs or TEs (Figure 1). Natural forms of vitamin E exist in the RRR-configuration 
(TOH) or the R-configuration (TE), whereas synthetic vitamin E is a mixture of the different 
stereoisomers (extensively reviewed in manuscript VI (Kluge et al. 2016)). Interestingly, due 
to its ability to preserve fertility in rats as well as preventing ataxia with vitamin E deficiency 
(AVED) in humans, α-TOH is the only form of vitamin E with proven vitamin property (Azzi 
2019). 
 
Figure 1: The different forms of TOHs and TEs. Vitamin E related structures are not shown. 
Adapted from (Kluge et al. 2016). 
2.1 Milestones in vitamin E research 
In a recently published article, Birringer et al. presented their personal selection of key findings 
in vitamin E history (Birringer et al. 2019). The following section will provide a modified version 
of this selection, which is predominantly focused on milestones of the current research on 
vitamin E long-chain metabolites (LCMs) as well as on previous findings that enabled their 
discovery (Figure 2).  
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The discovery of vitamin E (1922)  
In 1922, Katherine J. Scott Bishop and Herbert M. Evans observed that rats fed with a diet 
containing casein, cornstarch and lard supplemented with butterfat and salt are not capable 
of reproduction (Evans und Bishop 1922). However, the ability for reproduction was restored 
after the rats received fresh green leaves of lettuce. Based on this observation, Evans and 
Bishop concluded that natural food contains a ‘factor X’ that prevents sterility (Evans und 
Bishop 1922). After the description of its chemical and biological activities, the unknown 
compound was named ‘α-tocopherol’ (‘tokos’ = childbirth and ‘phero’ = to bear) (Evans et al. 
1936). The ability to prevent free radical induced lipid oxidation made α-TOH the most 
important lipid ‘chain-breaking’ antioxidant (Weber et al. 2019). The first characterization of 
the α-TOH structure was presented in 1938 by the German chemist Erhard Fernholz (Fernholz 
1938). In the same year Paul Karrer and Otto Isler accomplished the first chemical synthesis 
of DL α-TOH (Karrer et al. 1938).  
 
Figure 2: Milestones of vitamin E and LCM research. Adapted from (Birringer et al. 2019). 
LCM (long-chain metabolite). 
Discovery of vitamin E metabolism (~ 1984) 
In 1984, Chiku et al. unrevealed the metabolism of vitamin E in a rat model. After the 
administration of deuterated δ-TOH, the scientist were able to detect the water-soluble short-
chain metabolite (SCM) δ-carboxy-ethyl-hydroxychromanol (CEHC) – the end product of 
vitamin E metabolism – in urine of the rats (Chiku et al. 1984). Beside δ-CEHC, the occurrence 
of structurally related α- and γ-CEHC was also described. The discovery of vitamin E 
metabolism was a key finding for later LCM research, since it in principle promoted the 
investigation on vitamin E metabolites.  
Discovery of non-anti-oxidative functions of vitamin E (~ 1988) 
Azzi and colleagues were the first to describe a non-anti-oxidative function of vitamin E. They 
showed that protein kinase C activity could be inhibited by α- or β-TOH (Mahoney und Azzi 
1988). In addition, further specific non-anti-oxidative functions, such as inhibition of platelet 
adhesion and aggregation, inhibition of 5-lipoxygenase (5-LO) activity and modulation of α-
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tocopherol transfer protein (α-TTP) expression, have been described for RRR-α-TOH (Znigg 
und Azzi 2004). In the 2000s, an additional gene regulatory potential was discovered for TOHs 
and TEs (Landes et al. 2003; Landrier et al. 2009; Valastyan et al. 2008).  
Biological function and semi-synthesis of vitamin E long-chain metabolites (2010) 
In 2010, an investigation of Birringer et al. provided two milestones in the field of LCM 
research: (i) It was shown that vitamin E-derived LCMs reveal pro-apoptotic and anti-
proliferative activities in the human liver cancer cell line HepG2. Interestingly, the respective 
vitamin precursors showed no effect on cell viability or proliferation (Birringer et al. 2010). (ii) 
Birringer et al. provided a simplified route for the semi-synthesis of α- and δ-LCMs from the 
natural compound δ-tocotrienolic acid (δ-TE-13’-COOH), better known as garcinoic acid (GA). 
The study of Birringer et al. was the initial description of a biological activity of the vitamin E-
derived LCMs and the study provided first hints that the LCMs could probably represent the 
biologically active forms of TOHs and TEs. In addition, the described semi-synthetic route 
enabled the production of large amounts of α- and δ-LCMs in high purity, which had a major 
impact on future LCM research (Birringer et al. 2010). 
Evidence for a systemic relevance of vitamin E long-chain metabolites (2014) 
In 2014, Wallert et al. were the first to detect α-tocopherol-derived 13’-carboxychromanol (α-
T-13’-COOH) in the serum of a healthy, middle-aged, non-smoking male, who received a 
balanced diet with no additional supplementation of vitamin E (Wallert et al. 2014b). Hence, 
Wallert and coworkers hypothesized that the LCMs are likely formed during the hepatic 
metabolism of vitamin E. Afterwards, the newly formed metabolites are transferred into blood 
circulation, which enables their transport to various sites of action. This was a key finding in 
the field, since it provided evidence for a systemic relevance of the LCMs, at least for the α-
forms. The occurrence of α-T-13’-COOH in human blood was later confirmed by others 
(Torquato et al. 2016b; Pein et al. 2018).  
Selective uptake of α-T-13’-COOH into immune cells (2018) 
The concept that vitamin E-derived LCMs are transferred to peripheral tissues of the human 
body to convey regulatory effects, raised a central question: Are the metabolites absorbed by 
peripheral cells and tissues? In 2018, Pein et al. were the first to show the selective uptake of 
α-T-13’-COOH by murine peritoneal leukocytes. In addition, their investigation also provided 
a description of uptake kinetics for vitamin E LCMs (Pein et al. 2018), which represented a 
great limitation of previous in vitro studies on that topic.   
2.2 Recommendations for vitamin E intake 
The recommendations for the dietary intake of vitamin E vary between different nutritional 
authorities, depending on the biomarkers chosen to set their reference values. To overcome 
these differences, a recent publication suggested to consistently base the intake 
recommendations for vitamin E on its anti-oxidative activity in lipophilic compartments 
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(Raederstorff et al. 2019). In line with this concept, the reference values of the German Society 
of Nutrition (DGE) are based on the capacity of the respective vitamin E form to prevent lipid 
peroxidation. In the D-A-CH area (Germany, Austria, Switzerland), a daily vitamin E intake of 
12 - 15 α-tocopherol equivalents (TEQ) is recommended for adults (DGE 2019). The calculation 
of a TEQ is based on the determination of the biological activity of the respective TOHs and 
TEs in a fetus absorption test in rats (Kamal-Eldin und Appelqvist 1996). For example, 1 mg α-
TOH corresponds to one TEQ, while 1 mg γ-TOH only corresponds to 0.1 TEQ. In contrast, the 
recommended daily dose (RDD) of vitamin E in the USA (15 mg/d) is based on the amount of 
vitamin E that was necessary to avoid peroxide-induced hemolysis of blood samples from 
vitamin E deficient people (Péter et al. 2019). However, the use of this biomarker for the 
calculation of the daily vitamin E supply is controversially discussed (Azzi 2018). An overview 
about the recommendations of different national and international authorities is provided in 
Table 1.  
Table 1: Recommended daily intake of vitamin E by countries and organizations worldwide. 
Adapted from (Péter et al. 2019). D-A-CH (Germany-Austria-Switzerland), EFSA (European 
Food Safety Authority), IOM (US Institute of Medicine of the National Academy of Science), 
NCM (Nordic Council of Ministers), WHO/FAO (World Health Organization/Food and 









Age (years) ≥ 19 ≥ 10 ≥ 18 ≥ 19 ≥ 19 - 50 
Men 
(mg/day) 
12 - 15 13 10 10 15 
Women 
(mg/day) 
11 -12 11 8 7.5 15 
2.2.1 Vitamin E supply 
In a recent meta-analysis on global vitamin E supply, a median intake of 6.2 mg/d α-TOH and 
1 mg/d γ-TOH was calculated using data of 249 637 participants from 46 countries. Based on 
a recommended daily intake of 15 mg α-TOH (for adults), 82% of the global population was 
insufficiently supplied with vitamin E (Péter et al. 2019). Interestingly, the level of vitamin E 
supply was highly dependent on the geographical region. While 91% of the American 
population were below the RDD of 15 mg α-TOH, only 55% of the European population 
revealed an insufficient α-TOH supply (Péter et al. 2019). In Germany, the vitamin E supply of 
about 50% of the adult population was below the DGE recommendation of  12 - 15 TE/d (MRI 
2008). However, vitamin E undersupply had no influence on the general health status. 
Therefore, scientist are currently discussing an adjustment of the reference values (Péter et 
al. 2019). 
2.2.2 Vitamin E status 
The US Food and Nutrition Board defined a α-TOH plasma concentration of 12 μmol/l as a cut-
off value for vitamin E deficiency in healthy adults, since plasma levels below 12 μmol/l were 
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associated with miscarriage and increased erythrocyte fragility (IOM 2000; Shamim et al. 
2015). In addition, plasma α-TOH levels of < 8 μmol/l led to the development of ataxia, 
peripheral neuropathy or skeletal myopathy (Péter et al. 2019). It was also shown that low 
plasma α-TOH concentrations are linked to an increased risk for mild cognitive impairments 
and Alzheimer’s disease (Mangialasche et al. 2012). In contrast to the negative effects of 
vitamin E deficiency, different epidemiological studies provided evidence that α-TOH 
concentrations of ≥ 30 μmol/l are associated with health benefits (Péter et al. 2019). This 
concept is strengthened by the finding that urinary excretion of α-CEHC increases at a α-TOH 
serum threshold of 30 μmol/l, which is suggested as an indicator for sufficient vitamin E supply 
(Lebold et al., 2012). Unfortunately, the unadjusted worldwide median for circulating α-TOH 
was determined as only 22.1 μmol/l (Péter et al. 2019). Interestingly, plasma vitamin E 
concentrations above 45 μmol/l – resulting from pharmacological interventions – were 
associated with therapeutic benefits on immune function, cardiovascular health, liver health 
and cognitive function (Table 2) (Péter et al. 2019).  
Table 2: Concept of a dual distribution of vitamin E roles in human health. Adapted from 
(Péter et al. 2019). CV (cardiovascular) 
Vitamin E Essentiality Health benefits 
Status Deficient Suboptimal Desirable Therapeutic 
Serum 
concentration 
≤ 12 μmol/l 13 - 29 μmol/l 30 - 44 μmol/l ≥ 45 μmol/l 
Intake < 15 IU/day 15 - 54 IU/day 55 - 249 IU/day ≥ 250 IU/day 



















The intake of vitamin E from different food sources is generally considered safe. However, 
different national and international authorities have established a vitamin E intake of 300 – 
1000 mg/d as the upper tolerable intake level (EFSA, Panel on Dietetic Products, Nutrition and 
Allergies 2015; US National Research Council und US Institute of Medicine 2000). In line with 
this, the administration of a single dose of 300 mg mixed TEs did not led to any adverse effects 
in healthy volunteers (Yap et al. 2001). Nevertheless, the potential toxicity of vitamin E has 
always been an issue in the scientific community. For example, animal studies revealed that 
persistent high-dose vitamin E supplementation interfered with blood clotting and was 
therefore associated with an increased risk of hemorrhagic stroke (Zondlo Fiume 2002). 
Further, a meta-analysis from 2005 provided evidence that vitamin E supplementation with at 
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least 400 IU/d increases cancer risk and all-cause mortality, which had a great impact on the 
discussion about the toxicity of vitamin E (Miller et al. 2005). However, these results have been 
disproved by a recent meta-analysis. Here, the analysis of 250 000 participants with a vitamin 
E supplementation between 16.5 and 5000 IU/d showed no clear evidence that vitamin E 
increases all-cause mortality in humans (Köpcke 2019). Therefore, vitamin E intake seems to 
be safe even at much higher doses than the current RDD of 15 mg α-TOH per day. 
2.3 Digestion of vitamin E 
Based on its lipophilic character, dietary vitamin E is primarily ingested from lipid-rich foods. 
Especially plant-based oils, such as wheat germ oil (151 - 192 mg α-TOH/100 g), sunflower oil 
(33 - 59 mg α-TOH/100 g) or soya oil (61 - 70 mg γ-TOH/100 g) contain relatively high amounts 
of vitamin E (Shahidi und Camargo 2016).  
2.3.1 Bioavailability of vitamin E 
The bioavailability of vitamin E depends on different factors that have been summarized by 
Borel et al. with the acronym ‘SLAMENGHI’. Each letter stands for one factor: (S) species of 
vitamin E, (L) linkage (e.g. esterification of vitamin E), (A) amount of vitamin E in the meal, (M) 
matrix in which vitamin E is incorporated, (E) effectors of absorption and bioconversion (e.g. 
lipids, fiber, drugs), (N) Nutrient (i.e. vitamin E) status of the host, (G) genetic factors, (H) host-
related factors (e.g. sex, age), (I) mathematical interactions (e.g. to differentiate between 
single and combination effects) (Borel et al. 2013). The concept of Borel et al. is strengthened 
by findings from other studies: (i) Unconjugated natural RRR-α-TOH has the highest absorption 
rate of all vitamin E forms (Nagy et al. 2013). (ii) The bioavailability of vitamin E increases due 
to the parallel ingestion of lipids (Bruno et al. 2006). (iii) The bioavailability of vitamin E varies 
between different food matrices (Jeanes et al. 2004). In addition, different human studies 
observed an absorption rate between 55 and 81% of the administrated α-TOH (Mac Mahon 
und Neale 1970; Novotny et al. 2012). The peak concentration of α-TOH in plasma was reached 
5 h and 9 h post-administration.(Mac Mahon und Neale 1970).  
2.3.2 Intestinal absorption and distribution of vitamin E 
The intestinal absorption of vitamin E follows that of other lipophilic molecules (Rigotti 2007). 
Initially, the consumed vitamin E is released from its food matrix due to enzymatic processing 
by gastric lipases in the stomach (Borel et al. 2013). Further digestion of vitamin E appears in 
the intestinal lumen, where, among others, vitamin E esters from supplements, such as 
tocopherol acetate, are hydrolyzed to a non-esterified form. The emulsification of vitamin E 
and other lipophilic molecules is accomplished by bile acids, i.e. free vitamin E is incorporated 
into micelles formed with phospholipids and bile acids (Flory et al. 2019). Afterwards, the 
micelles are taken up by enterocytes via passive diffusion or receptor-mediated transport. The 
scavenger receptor class B type 1, the cluster of differentiation 36 (CD36) or the Niemann-Pick 
C1-like protein 1 were identified as receptors involved in the intestinal uptake of vitamin E 
(Reboul 2017; Goncalves et al. 2014; Yamanashi et al. 2017). Afterwards, vitamin E is 
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integrated into chylomicrons and secreted into the lymphatic system (Hacquebard und 
Carpentier 2005). Vitamin E secretion from enterocytes requires active transport via ATP-
binding cassette transporter A1 (ABCA1) (Schmölz et al. 2016). After entering the circulation, 
chylomicrons are degraded by lipoprotein lipase (LPL), leading to the formation of chylomicron 
remnants (Hacquebard und Carpentier 2005). Vitamin E is not affected by LPL mediated 
hydrolysis of triglycerides and remains in the lipoprotein particle for further transport to the 
liver (Julve et al. 2016). Here, the chylomicron remnants are taken up by the hepatic low-
density lipoprotein receptor-related protein 1 (Basford et al. 2011). The different forms of 
vitamin E are likely discriminated by α-TTP that promotes the incorporation of 2R- or RRR-α-
TOH into very low-density lipoproteins (VLDL), while other vitamin E forms are either 
metabolized to their respective CEHCs for urinary excretion or secreted into bile. After its 
release from the liver due to the activity of ABCA1, α-TOH is incorporated into VLDL particles 
and transferred to extrahepatic tissues (Flory et al. 2019). 
2.3.3 Storage of vitamin E 
Due to its lipophilic character, vitamin E can be stored in different depots of the human body. 
A study in rats revealed that 90% of the overall α-TOH is stored in skeletal muscle (42%), the 
liver (28%) or in adipose tissue (21%) (Uchida et al. 2011; Bjørneboe et al. 1990). In general, 
the liver seems to be responsible for short-term storage, while the adipose tissue enables 
long-term storage of vitamin E (Machlin und Gabriel 1982). In vitro, vitamin E is predominantly 
located in cell membranes or cellular lipid-rich factions as well as in cytosolic lipid droplets 
(Saito et al. 2004; Traber und Kayden 1987). Interestingly, the intracellular TOH amount 
depends on the lipid content of the respective cell type (Saito et al. 2004).  
2.4 Hepatic metabolism of vitamin E 
The concept of vitamin E catabolism in the human body was already proposed in 1956 due to 
the detection of tocopheronic acid and tocopheronolactone, better known as Simon products, 
in human urine (Simon et al. 1956). The formation of Simon products was thought to occur 
because of an opening of the chromanol ring after a radicalic attack, leading to the formation 
of tocopherol quinone that is further degraded to tocopheronic acid and tocopheronelactone 
(Schmölz et al. 2016). However, this concept was disproved due to the discovery of δ-CEHC – 
a degradation product of δ-TOH with an intact chromanol ring and a shortened side chain – in 
human urine (Chiku et al. 1984). Interestingly, the Simon products were later identified as 
artifacts of the sample preparation process (Znigg 2007).  
2.4.1 Principles of vitamin E metabolisation 
This section will only provide a short overview about the key reactions of vitamin E 
degradation (Figure 3). For a detailed description of the vitamin E metabolism, the reader is 
referred to the manuscripts VI and VII. The metabolism of vitamin E in humans is 
predominantly localized in the liver. Interestingly, the metabolism can be increased in the 
presence of higher vitamin E levels to prevent toxic accumulation. 
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Figure 3: The hepatic metabolism of vitamin E. Adapted from (Schmölz et al. 
2018). CEHC (carboxy-ethyl-hydroxychromanol), ICM (intermediate-chain 
metabolites), LCM (long-chain metabolites), SCM (short-chain metabolites). 
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The hepatic metabolism takes place in three different compartments: (i) endoplasmic 
reticulum, (ii) peroxisomes and (iii) mitochondria (Schubert et al. 2018).In general, the 
degradation of all TOH and TE forms follows the same metabolic route, which has been 
confirmed by the detection of α-, β-, γ- and δ-CEHC in urine (Chiku et al. 1984; Schultz et al. 
1995; Swanson et al. 1999). Further, the classification of CEHCs as the metabolic endproducts 
of vitamin E catabolism indicates that only the side chain is modified during this process while 
the chromanol ring stays intact. In addition, the metabolisation of TEs require further 
enzymes, such as 2,4 dienoyl-CoA reductase and 3,2-enoyl-CoA isomerase that are likely 
necessary for the degradation of the unsaturated side chain (Birringer et al. 2002). The initial 
and rate-limiting step of vitamin E metabolism is the formation of 13’-hydroxychromanol (13’-
OH) metabolites via ω-hydroxylation of the terminal side chain by cytochrome P450 (CYP) 4F2 
or CYP3A4 (Sontag und Parker 2002; Parker et al. 2000). Next, the terminal side chain of 13’-
OH undergoes α-oxidation in the peroxisomes, resulting in the formation of 13’-
carboxychromanol (13’-COOH). This reaction is probably mediated by alcohol- or aldehyde 
dehydrogenases, because an aldehyde intermediate is formed during the oxidation process. 
The mechanism for the further degradation of 13’-COOH is comparable to the degradation of 
branched-chain fatty acids. Hence, the terminal side chain is shortened by a stepwise removal 
of two carbon units via multiple β-oxidation cycles (Schubert et al. 2018). Overall, five β-
oxidation cycles are necessary until the formation of the water-soluble end-product 3’-COOH, 
better known as CEHC (Birringer et al. 2001). The water-soluble SCMs are excreted via urine, 
while the LCMs and intermediate-chain metabolites (ICMs) are secreted into bile (Zhao et al. 
2010). Because of enzymatic modifications during the hepatic metabolism, most of the urinary 
SCMs can be detected as sulfated- or glucuronidated conjugates (Birringer et al. 2001). In 
contrast, the lipophilic LCMs are predominantly excreted in their unconjugated form (Zhao et 
al. 2010).   
2.4.2 Metabolisation efficiency  
The metabolisation efficiency of the different vitamin E forms depends on at least three 
different factors: (i) the substitution of the chromanol ring, (ii) the saturation of the side chain 
and (iii) the source from which the vitamin is obtained (natural or synthetic) (Schmölz et al. 
2016). The degradation rate of the vitamin E isoforms is decreased with an increasing number 
of methyl groups substituted to the chromanol ring (δ > γ/β > α-TOH/TE). Indeed, human trials 
revealed that round about 50% of the ingested γ-TOH are metabolized to γ-CEHC and excreted 
via urine, while only 1 - 3% of the consumed α-TOH were degraded to α-CEHC (Swanson et al. 
1999; Schuelke et al. 2000). Further, the degradation of TOHs is less efficient compared with 
TEs. Interestingly, synthetic vitamin E forms revealed the highest and natural RRR-α-TOH the 
lowest metabolic rate (Sontag und Parker 2007).  
2.4.3 Verification of systemic LCM availability 
The discovery of vitamin E metabolism in humans together with the emerging evidence for 
important biological function of vitamin E LCMs, led to the hypothesis that the hepatic 
metabolism converts TOHs and TEs to their active forms (already described for the vitamins A 
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and D (Schubert et al. 2018)). In 2014, Wallert and coworkers detected nanomolar levels of α-
T-13’-COOH in human serum, which was later confirmed by others (Wallert et al. 2014b; 
Torquato et al. 2016b; Giusepponi et al. 2017; Pein et al. 2018). The study showed for the first 
time that vitamin E LCMs are transferred into the blood circulation, providing strong evidence 
for their systemic relevance in the human body.  
3 Long-chain metabolites of vitamin E 
All TOH- and TE-derived metabolites with a side chain length between 13 and 9 carbon units 
are entitled as LCMs. Within these molecules, 13′-OHs and 13′-COOHs metabolites have 
emerged as promising bioactive molecules with a possible relevance for the regulation of 
physiologic functions. The growing interest on this new aspect of vitamin E research led to a 
significant increase of knowledge about the LCMs. This includes approaches for their 
standardized synthesis, analytical strategies for their determination in various matrices as well 
as the description of a variety of new biological functions.  
3.1 Synthesis of vitamin E long-chain metabolites 
 
Figure 4: Semisynthesis of α-T-13’- and δ-T-13’-LCMs of vitamin E from garcinoic acid (δ-
TE-13’-COOH). Changes in the structure of the respective compound after every synthesis 
step are marked in red. Adapted from (Birringer et al. 2010). PtO2 (platinum dioxide); HCHO 
(formaldehyde); SnCL2 (tin(II) chloride); LiAIH4 (lithium aluminium hydride). 
The incubation of cultured cells – possessing enzymatic systems necessary for vitamin E 
metabolism – with TOHs or TEs represented a common method for the generation of LCMs. 
After sufficient incubation time, the newly formed metabolites can be obtained from the cell 
culture supernatant (Jiang et al. 2007; You et al. 2005; Jiang et al. 2008). However, this method 
has several disadvantages, since the cells produced a non-standardized mixture of LCMs, ICMs 
and SCMs in their conjugated or unconjugated form. Hence, it was necessary to generate the 
respective compounds in high purity to simplify the investigation of a single metabolite. In line 
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with this, Mazzini et al. and Birringer et al. developed a standardized semisynthesis for the α- 
and δ-LCMs from the natural compound GA (Mazzini et al. 2009; Birringer et al. 2010). 
Garcinoic acid or trans-δ-TE-13’-COOH can be obtained from the seeds of Garcinia kola E. 
Heckel (manuscript VI (Kluge et al. 2016)). The method for the isolation of GA was initially 
described by Terashima et al. in 1997 and has been further improved by Birringer et al. and 
Wallert et al. (Terashima et al. 1997; Birringer et al. 2010; Wallert et al. 2019). For a detailed 
description of the procedure, the reader is referred to manuscript IV. In addition to its isolation 
from natural origins, chemical synthesis of GA was also described (Maloney und Hecht 2005). 
The semisynthesis of the α- and δ-LCMs from GA is achieved in three steps (Figure 4): (i) The 
unsaturated side chain of GA is hydrogenated in a platinum-catalyzed reaction that leads to 
the formation of δ-T-13’-COOH. (ii) The corresponding α-form, α-T-13’-COOH, is obtained by 
a SnCl2 catalyzed permethylation of δ-T-13’-COOH, i.e. the addition of two methyl groups to 
the chromanol ring. (iii) The respective T-13’-OH forms can be generated via reduction of δ-T-
13’-COOH or α-T-13’-COOH with LiAlH4 (Mazzini et al. 2009; Birringer et al. 2010). For a 
detailed description of the semisynthetic route, the reader is referred to manuscript VI (Kluge 
et al. 2016).  
3.2 Analysis of vitamin E long-chain metabolites 
To date, a variety of different analytical approaches for the detection of vitamin E LCMs in 
cells, cell culture supernatant, human serum and plasma, tissues and feces have been 
published. However, the following section will only provide a short overview about the basics 
of LCM analysis. For more details, the reader is referred to manuscript IX (Kluge et al. 2019).  
Enzymatic deconjugation of the LCMs in a sample matrix was established as the initial step in 
current analytical procedures, since it improves their recovery for the later analysis (Wallert 
et al. 2014b). The subsequent extraction of the LCMs is accomplished by liquid-liquid or solid-
phase extraction (Yang et al. 2010; Wallert et al. 2014b; Ciffolilli et al. 2015; Giusepponi et al. 
2017). The extracted metabolites are afterwards separated by high performance liquid 
chromatography (HPLC) or gas chromatography (GC) coupled to different detectors. Here, the 
expected LCM concentration in the respective sample is crucial for the selection of a suitable 
detection method. While fluorescence detection is sufficient for cell culture samples, the 
analysis of LCMs in human plasma or serum requires detection via mass spectrometry (MS) 
(Kluge et al. 2019). A subset of analyzable LCMs in human blood is provided in Table 3. 
Challenges of LCM analysis in human blood 
The detection of LCMs in human blood appeared as one of the greatest challenges of vitamin 
E research in the last decade. As already mentioned, serum concentrations of α-T-13’-COOH 
and α-T-13’-OH are at low nanomolar levels. Hence, their analysis requires high sensitive 
detection methods, e.g. LC-MS/MS or GC-MS/MS, as well as specific sample preparation 
procedures that increase their recovery, i.e. enzymatic deconjugation of the LCMs by sulfatase 
and β-glucuronidase (Wallert et al. 2014b). Since the initial detection of α-T-13’-COOH in 
human serum, analytical approaches for vitamin E LCMs were constantly improved over time 
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(Ciffolilli et al. 2015; Torquato et al. 2016b). The latest procedure enabled the simultaneous 
detection of α-T-13’-COOH and α-T-13’-OH together with their vitamin precursors in the same 
sample (Giusepponi et al. 2017). However, there are still problems to solve. It was recently 
recognized that the blood concentration of α-T-13′-COOH is probably detected as a bulk 
parameter comprised of up to three different isomers (Giusepponi et al. 2017). Unfortunately, 
the origin of these stereoisomers is currently unknown, but their separation and 
characterization represents a challenge for future analytical procedures, since it would shed 
light on the question whether the proposed systemic relevance of vitamin E LCMs depends on 
a specific isomer.  
Table 3: Subset of analyzable LCMs in human blood with their corresponding preparation 
and detection methods. Adapted from (Kluge et al. 2019). Deconj. (deconjugation); Extr. 
(extraction); G (glucoronidase); LC (liquid chromatography); LL (liquid-liquid); n.i. (no 
information); Q-TOF (quadrupole time-of-flight); S (sulfatase) 
Deconj. Extr. Chromatography Sample Metabolite Reference 
S + G LL Q-TOF-LC-MS Human serum α-T-13’-COOH 





Human serum α-T-13’-OH 
(Ciffolilli et al. 
2015) 
n.i. LL LC-MS/MS Human serum 
α-T-13’-COOH 
α-T-13’-OH 
(Torquato et al. 
2016b) 





(Giusepponi et al. 
2017) 
n.i. LL UPLC-MS/MS 
Human 
plasma 
α-T-13’-COOH (Pein et al. 2018) 
3.3 Biological activities of vitamin E long-chain metabolites 
Since the initial description of an inhibitory effect of γ- and δ-T-13’-COOH on the activity of  
cyclooxygenase (COX)-2 in human lung carcinoma A549 cells (Jiang et al. 2008), the interest 
on the biological functions of vitamin E LCMs has constantly grown over the years. Today, the 
variety of known biological effects of the LCMs can be categorized as follows: (i) anti-
inflammatory activity, (ii) anti-carcinogenic effects, (iii) regulation of cellular lipid homeostasis, 
(iv) interaction with pharmaceuticals, and (v) regulation of vitamin E metabolism. Since their 
biological activities have been extensively reviewed in the manuscripts VI to X, the following 
sections will only provide a compact overview about the most important effects of the LCMs. 
For a more detailed description, the reader is referred to the respective manuscripts.  
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3.3.1 Anti-inflammatory activities 
Inflammation is a key factor in the pathogenesis of several non-communicable human 
diseases such as metabolic syndrome, diabetes mellitus, cardiovascular disease, 
neurodegenerative disease and cancer (Okin und Medzhitov 2012). The complex process of 
systemic inflammation is triggered by different key factors, including pro-inflammatory 
enzymes, chemokines and cytokines (Schubert et al. 2018). Hence, research on the anti-
inflammatory actions of vitamin E-derived LCMs predominantly focused on these targets. To 
date, several LCMs, such as α-, γ-, and δ-T-13’-COOH, δ-T-9’-COOH as well as α- and δ-T-13’-
OH, were shown to reduce stimulus-induced expression, activity or production of different 
pro-inflammatory factors (Wallert et al. 2020).  
Treatment with 10 μM of either α-T-13’-OH or δ-T-13’-OH decreased the expression of 
inducible nitric oxide synthase (iNOS) and COX-2 in lipopolysaccharide (LPS)-stimulated 
murine RAW264.7 macrophages (Ciffolilli et al. 2015; Schmölz et al. 2017). In addition, 
interleukin (IL)-β and IL-6 mRNA expression as well as prostaglandin (PG) E2 production was 
also reduced by α-T-13’-OH (10 μM) (Ciffolilli et al. 2015). The carboxy metabolites α-T-13’-
COOH and δ-T-13’-COOH revealed similar effects in LPS-stimulated murine RAW264.7 
macrophages, although lower concentrations (5 μM) were necessary to reduce the expression 
of iNOS, COX-2 and pro-IL-1β (Schmölz et al. 2017; Wallert et al. 2015). Interestingly, only δ-
T-13’-COOH (5 μM) decreased the enzymatic activity of COX-2, while α-T-13’-COOH (5 - 10 
μM) showed no effect (Jiang et al. 2008; Wallert et al. 2015; Pein et al. 2018). Nevertheless, 
α-T-13’-COOH blocked the LPS-induced production of nitric oxide and PGE2 in murine 
macrophages (5 μM) (Wallert et al. 2015). Beside the mentioned effects on iNOS and COX-2, 
α-T-13’-COOH also reduced 5-lipoxygenase (LO) product formation, i.e. production of 
leukotriene (LT)B4),  in vitro and in vivo (Pein et al. 2018). Compared with TOH-derived LCMs, 
the knowledge on anti-inflammatory activities of TE-derived LCMs is sparse. However, δ-TE-
13’-COOH (5 μM) (i.e. garcinoic acid) reduced the expression of iNOS, COX-2, pro-IL-1β, IL-6 
and TNF-α as well as the formation of their respective products, i.e. nitric oxide, PGE2, and 
thromboxane (TX)B2, in LPS-stimulated murine RAW264.7 macrophages (manuscript IV 
(Wallert et al. 2019)). In addition, PGE2 formation in LPS-stimulated monocytes was already 
inhibited at a δ-TE-13’-COOH concentration of 300 nM (Pein et al. 2018).  
3.3.2 Anti-carcinogenic effects 
Abnormal proliferation together with a reduced rate of apoptosis are two major 
characteristics of cancer cells. Thus, current cancer therapies predominantly rely on drugs that 
are able to kill cells with high rates of proliferation and regeneration. Interestingly, natural 
compounds with anti-proliferative or pro-apoptotic activities are regarded as beneficial in the 
prevention and treatment of cancer, as they generally exert less side effects compared with 
conventional drugs (Schubert et al. 2018). To date, several natural compounds, including the 
LCMs of vitamin E, have been identified to affect key factors of cancer development.  
In an investigation in the human liver cancer cell line HepG2, α-T-13’-COOH (20 μM) and δ-T-
13’-COOH (20 μM) caused cell growth arrest, while their corresponding 13’-OH metabolites 
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did not affect cell proliferation. Further, α- and δ-T13’-COOH as well as δ-T-13’-OH reduced 
cell viability of HepG2 cells via induction of pro-apoptotic pathways, indicated by an enhanced 
cleavage of poly[ADP-ribose]-polymerase 1 and caspases 3, 7 and 9 (Birringer et al. 2010). The 
observed pro-apoptotic effects of α-T-13’-COOH and δ-T-13’-COOH were confirmed in human 
leukemia-derived THP-1 macrophages (IC50 of 7.4 μM or 11.1 μM respectively) (Wallert et al. 
2014b; Schmölz et al. 2017). In addition, anti-proliferative and pro-apoptotic effects of δ-T-
13’-COOH were also described in human HCT-116 colon carcinoma cells (IC50 8.9 μM) and 
human HT-29 colorectal adenocarcinoma cells (IC50 8.6 μM) (Jang et al. 2016). So far, δ-TE-13’-
COOH (i.e. garcinoic acid) is the only TE-derived LCM with a known anti-carcinogenic potential. 
Garcinoic acid decreased the viability of human HCT-116 colon carcinoma cells, human HT-29 
colorectal adenocarcinoma cells (Jang et al. 2016) and human glioma C6 cells (Mazzini et al. 
2009) as well as colon tumor growth in BALB/c mice (Jang et al. 2016).  
3.3.3 Effects on lipid homeostasis 
Only a few modulatory activities of the LCMs on different facets of the cellular lipid 
homeostasis have been described so far. These include regulation of CD36 and regulation of 
perilipin 2 (PLIN2), better known as adipophilin, mediation of the uptake of oxidized low-
density lipoproteins (oxLDL), phagocytosis as well as intracellular storage of lipids. Overall, 
these results indicate that the LCMs could be involved in the regulation of macrophage foam 
cell formation, a hallmark in the pathogenesis of atherosclerosis.  
The LCMs α-T-13’-COOH (5 μM) and α-T-13’-OH (10 μM) induced CD36 expression in human 
leukemia-derived THP-1 macrophages and primary macrophages (Wallert et al. 2014b). In 
addition, ox-LDL induced CD36 expression – a pathophysiologic positive feedback loop in 
macrophage foam cell formation – was augmented by α-T-13’-COOH and α-T-13’-OH. 
Surprisingly, oxLDL uptake into THP-1 macrophages decreased after pre-incubation with 
either α-T-13’-COOH (20%) or α-T-13’-OH (24%). In line with this, cellular neutral lipid 
accumulation was also not increased. These contradictory results were at least in parts 
explained by a reduction of oxLDL uptake via phagocytosis after LCM treatment (Wallert et al. 
2014b). Besides their interaction with oxLDL uptake, LCMs also affected intracellular lipid 
storage. Hence, α-T-13’-COOH (5 μM) induced the expression of PLIN2 as well as the size and 
number of intracellular lipid droplets in human THP-1 macrophages. Further, α-T-13’-COOH 
was able to protect THP-1 cells from stearic acid induced lipotoxicity, which was at least in 
parts attributed to the upregulation of PLIN2 expression (Schmölz et al. 2018). In addition to 
the already existing knowledge about the interference of α-T-13’-COOH with the cellular lipid 
homeostasis, manuscript I provides new insights into another aspect of the regulatory role of 
α-T-13’-COOH on macrophage foam cell formation. We here show for the first time that α-T-
13’-COOH (5 μM) is able to protect human THP-1 macrophages against excessive lipid 
accumulation in the presence of VLDL oversupply. The protective effect resulted from a very 
potent upregulation of angiopoietin-like (ANGPTL) 4 mRNA expression, which in turn 
decreased the LPL mediated uptake of lipids. Thus, manuscript I provides further evidence for 
an atheroprotective role of α-T-13’-COOH. 
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3.3.4 Other known biological effects 
3.3.4.1 Interaction with pharmaceuticals 
The expression of P-glycoprotein (P-gp) – a protein that regulates the intracellular 
concentration of pharmaceuticals – is among others regulated by the pregnane X receptor 
(PXR) (Dewanjee et al. 2017). Interestingly, α-T-13’-COOH enhanced P-gp expression in human 
epithelial-like colon LS180 cells  as well as the activity of PXR in a reporter gene assay (Podszun 
et al. 2017). In addition,  δ-TE-13’-COOH (i.e. garcinoic acid) was also proposed as a selective 
PXR agonist (Bartolini et al. 2020). 
3.3.4.2 Regulation of LCM formation 
So far, the regulatory mechanisms modulating the metabolism of vitamin E are still unknown. 
However, Torquato et al. showed that the expression of CYP4F2 – the rate limiting enzyme in 
vitamin E metabolism – was upregulated by α-T-13’-OH in human HepG2 cells (Torquato et al. 
2016a). This result provides evidence for a positive regulatory feedback loop of the LCMs on 
the metabolism of vitamin E. Interestingly, the positive feedback regulation would be in 
contrast to other fat-soluble vitamins, as the metabolism of vitamin A and D is negatively 
regulated by their metabolites (Schubert et al. 2018).  
3.3.4.3 Structure specific effects 
As already indicated, the different vitamin E forms and LCMs seem to reveal their biological 
activities with different efficiencies. To test this hypothesis, Schmölz et al. used the α- and δ-
forms of T-13’-OH and T-13’-COOH together with α- and δ-TOH to investigate their regulatory 
potential on CD36 and iNOS expression. Further, two additional substances representing 
specific substructures of the LCMs, i.e. the SCM α-CEHC mimicking the chromanol ring system 
as well as pristanic acid imitating the modified side chain, were also included in the 
investigation. All investigated LCMs revealed potent regulatory effects on the expression of 
CD36 and iNOS even at low concentrations. In contrast, neither their vitamin precursors nor 
the included substructures were able to accomplish comparable effects. Overall, the 13’-
COOH metabolites showed the most potent effects of all investigated compounds (Schmölz et 
al. 2017). 
4 Atherosclerosis 
Although most of the current studies on vitamin E-derived LCMs are focused on one specific 
functional aspect, the entirety of known biological activities can be assigned to different 
human diseases. For example, LCMs are involved in the regulation of inflammation and the 
cellular lipid homeostasis (especially in macrophages), two key factors for the pathogenesis of 
atherosclerosis. Atherosclerosis together with its complications stroke and myocardial 
infarction are by far the leading cause of death in industrialized Western societies (Cheng et 
al. 2020). Since atherosclerotic events increased over the last decades, their development 
seems to correlate with different factors of the modern lifestyle. This includes food oversupply 
and quality, lack of physical activity and smoking (Rafieian-Kopaei et al. 2014). The 
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development and progression of atherosclerosis is characterized by a complex interaction of 
different processes over a long time. In brief, different endogenous and exogenous noxes 
cause an initial endothelial dysfunction that leads to intimal thickening due to the recruitment 
of T-cells and monocytes into the subintimal space. The pathogenesis continues due various 
events, such as differentiation of monocytes to macrophages, lipid accumulation in 
macrophages as well as proliferation of lipid-loaded macrophages, deposition of cholesterol 
and fibrotic material, foam cell formation, fatty streak formation, elasticity loss and reduction 
of the vascular lumen with parallel widening of the arterial diameter. Finally, atherosclerotic 
changes of the intima lead to the formation of a necrotic lipid core with a fibrotic cap. 
Continuous destabilization of the fibrous cap by proteases results in plaque rupture and 
thrombus formation. Subsequently, the thrombus flows with the bloodstream and causes 
vascular occlusion in an artery with a smaller volume. The thrombus can also be integrated in 
the plaque, leading to the formation of a so-called complicated plaque (Wallert et al. 2014c).  
The pathogenesis of atherosclerosis as well as the potential therapeutic effect of vitamin E in 
large human intervention trials have been extensively reviewed by our group (the reader is 
referred to (Wallert et al. 2014c)). In addition, our previous investigations provided evidence 
for an association between the vitamin E-derived LCMs and classic key factors in the 
development of atherosclerosis, i.e. inflammation and oxLDL triggered foam cell formation 
(Wallert et al. 2014b; Wallert et al. 2015). The following section will therefore focus on a 
different aspect in the development of atherosclerosis, i.e. the triglyceride-rich lipoprotein 
(TRL) mediated foam cell formation. In line with this, manuscript I provides convincing 
evidence for a regulatory role of the vitamin E LCM α-T-13’-COOH in this underestimated part 
of the atherosclerotic process. 
4.1 The relevance of the forgotten lipids for atherosclerosis 
Elevated low-density lipoprotein (LDL) cholesterol is a well-established risk factor for the 
development of atherosclerosis. According to national and international guidelines, LDL 
cholesterol represents a key therapeutic target for the prevention and treatment of 
atherosclerosis (Stone et al. 2014; Mach et al. 2020). In line with this, LDL-lowering therapies, 
such as treatment with statins, ezetimibe, and proprotein convertase subtilisin-kexin type 9 
inhibitors, have been introduced in clinical practice (Cannon et al. 2015; Sabatine et al. 2017). 
However, despite of the significant reduction of LDL cholesterol levels by lipid-lowering 
agents, patients still reveal recurrent cardiovascular events (Sampson et al. 2012; Madsen et 
al. 2018). Interestingly, results from several large-scale epidemiological studies provided 
evidence for a casual association between TRLs, i.e. chylomicrons and VLDL, and 
atherosclerosis (Nordestgaard 2016). Outcomes from genetic studies further strengthened 
this concept. Here, genetic modification of key genes in TRL metabolism, such as Lpl, 
apolipoprotein (Apo) A-V, ApoC-III and Angptl4, strongly correlated with an increased risk for 
atherosclerotic events (Musunuru und Kathiresan 2016). Since TRLs represent the 
predominant carriers of triglycerides in blood, their concentration directly correlates with 
serum triglyceride level. Therefore, determination of serum triglycerides represents a valid 
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and established biomarker for the detection of enhanced TRL levels in humans. In accordance 
with the guidelines of the American Herat Association, moderate hypertriglyceridemia is 
defined by a fasting serum triglyceride level of  ≥ 150 mg/dL (1.7 mmol/L) (Miller et al. 2011). 
The moderate elevation of serum triglycerides is predominantly promoted by lifestyle factors, 
such as overweight, diets enriched in saturated fats and carbohydrates as well as excess 
alcohol consumption. Based on the results of national surveys, moderate hypertriglyceridemia 
was present in 32% of the American and in 27% of a comparable European population (Miller 
et al. 2011; Mortensen et al. 2015). Hence, moderate hypertriglyceridemia affects a significant 
part of the population, indicating the putative relevance of TRLs for the development of 
atherosclerosis in Western societies. Besides triglycerides, TRLs carry varying amounts of 
cholesterol, the so-called remnant cholesterol. The cholesterol amount of TRLs – especially of 
VLDL – was also considered as a crucial factor in TRL mediated development of atherosclerosis 
(Nordestgaard 2016).  
4.2 Mechanisms of TRL mediated development of atherosclerosis 
It was demonstrated that VLDL is able to penetrate the arterial wall to enter the intima, i.e. 
the site of plaque formation (Shaikh et al. 1991; Nordestgaard et al. 1992). In line with this, 
VLDL was detected as the predominant form of TRLs in atherosclerotic plaques (Nakano et al. 
2008). It is supposed that after VLDL entered the arterial wall, the lipoprotein particle is 
trapped by proteoglycans or other components of the intima, as it was already shown for LDL 
(Borén et al. 1998). Based on the available data, VLDL mediated atherosclerotic changes in the 
intima are probably promoted by two major mechanisms: (i) The triglycerides of the VLDL 
particles are degraded by the activity of LPL on the endothelial surface or the surface of 
macrophages and foam cells in atherosclerotic plaques (O'Brien et al. 1992; Kersten 2014). 
This leads to the liberation of free fatty acids that on the one hand cause local inflammation 
(Rosenson et al. 2014) and on the other hand promote macrophage foam cell formation 
(Skarlatos et al. 1993). (ii) Unlike LDL particles that require additional oxidative modification, 
VLDL particles can be directly taken up by macrophages due to the VLDL receptor (Miller et al. 
2010). The VLDL receptor functions as a peripheral lipoprotein receptor in concert with LPL, 
especially on the surface of macrophages (Takahashi et al. 2004; Takahashi 2017). Here, 
cholesterol content of VLDL seems to be the crucial factor for foam cell formation, like it has 
been shown for the uncontrolled uptake of oxLDL (Nordestgaard und Varbo 2014). 
Interestingly, some investigation suggested VLDL to reveal an even higher pro-atherogenic 
potential than LDL because of its facilitated uptake via the VLDL receptor (Toth 2016). Since 
both suggested mechanism directly or indirectly involve LPL, the LPL system (extensively 
reviewed in (Dijk und Kersten 2016)) seems to play a major role in TRL mediated development 
of atherosclerosis. This concept is further strengthened by the outcomes of a recent genetic 
study, showing that mutations of key genes in the LPL system, i.e. LPL and ANGPTL4 were 
correlated with an increased risk for atherosclerosis (Musunuru und Kathiresan 2016; Kersten 
2019). If this concept holds true, the LPL system would appear as a new target in the 
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prevention of atherosclerosis. A schematic overview of the general mechanisms in LPL 
promoted foam cell formation is provided in Figure 5. 
 
Figure 5: The LPL pathway and its potential involvement in foam cell formation and 
atherosclerosis. Adapted from (Tada et al. 2018). ANGPTL (angiopoietin-like), ApoC-II (apo 
protein C-II), FFA (free fatty acid), GPIHBP1 (glycosylphosphatidylinositol anchored high 
density lipoprotein binding protein 1), LD (lipid droplet), LPL (lipoprotein lipase), VLDL (very 
low density lipoprotein). Functional LPL homodimers are transferred to the endothelial 
surface where they bind to GPIHBP1. Here, functional LPL hydrolyzes the triglycerides of 
VLDL particles, which leads to the liberation of FFAs. In turn, absorption of high amounts of 
FFAs by macrophages promotes foam cell formation. Physiological regulator proteins, such 
as ANGPTL3 and ANGPTL4, are able to inhibit LPL activity, while other proteins, such as 
ApoC-II, promote LPL activity. Since it was shown that mutations of key genes in the LPL 
system, i.e. LPL and ANGPTL4, are associated with an increased risk for atherosclerosis, the 
LPL system seems to play a major role in VLDL-mediated atherogenesis. 
 
AIM OF THE THESIS  31 
5 Aim of the thesis 
Almost one hundred years after its discovery in 1922, the function of vitamin E in humans is 
still not elucidated. In a recent perspective on the occasion of the 100th anniversary of the 
discovery of vitamin E, the current state of research was summarized as follows: “[...] we have 
still more questions than answers regarding the biological functions and the essentiality of 
vitamin E for human health” (Galli et al. 2017). Nevertheless, vitamin E research made great 
progress over the last 100 years and is currently experiencing a scientific ‘renaissance’, which 
is among others attributed to the discovery of vitamin E metabolism in humans as well as the 
elucidation of biological functions of the formed metabolites. Especially since the 
determination of vitamin E LCMs in human serum – indicating their systemic relevance in the 
human body – it is becoming more and more evident that the essentiality of vitamin E for 
human health cannot be explained likely without the consideration of its metabolites. Thus, 
renowned scientist on the field hypothesized that the LCMs are not only side-products of 
vitamin E excess, but may represent activated and therefore functional molecules of their 
vitamin precursors (Galli et al. 2017). 
Hence, the major aim of this PhD thesis was to increase our knowledge on the function of 
vitamin E metabolites as well as to generate a significant contribution to the progress of this 
promising new facet of vitamin E research. In more detail, the thesis predominantly focused 
on four aims:  
(i)  The current knowledge about vitamin E-derived LCMs together with emerging aspects for 
future research should be provided to a broad scientific community due to the 
preparation of different review articles on their biological functions, chemical analysis and 
potential benefit for human health. This should contribute to increase the interest in this 
new research topic as well as to promote the generation of new working hypotheses for 
future studies.   
(ii)  The elucidation of additional regulatory functions of the vitamin E-derived LCMs in lipid 
metabolism and inflammation. The aim of these investigations was to deepen our insights 
into the modes of action of the LCMs as well as to derive potential functions relevant for 
human health, especially for atherosclerosis. This did also include the development of 
new methodical approaches, facilitating the investigation of different aspects of the LCM 
function.  
(iii) The generation of data further strengthening the concept that the vitamin E-derived LCMs 
represent functional molecules of their vitamin precursors. This should be achieved by 
the parallel investigation of LCMs and their respective vitamin precursor in vitro. If the 
concept holds true, this would also provide evidence for a general mechanism of 
metabolic activation for fat-soluble vitamins, as it was already described for the vitamins 
A and D (Schubert et al. 2018). 
(iv) The generation of convincing in vitro data, that justify future studies on the indicated 
systemic relevance of the vitamin E LCMs in vivo.  
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6 Manuscript overview 
The following section provides an overview about the publications and manuscripts included 
in this thesis. All publications deal with the topic of vitamin E and vitamin E-derived LCMs and 
were created by myself or in collaboration with me. A graphical overview about the thematic 
linkage of the individual publications together with a statement of my personal contribution 
to the respective manuscript (percentage) is provided in Figure 6. 
 
Figure 6: Schematic overview about the manuscripts included the thesis. Manuscripts 
marked in bold are first authorships. My personal contribution to the respective manuscript 
is stated as percentage. GA (garcinoic acid), LCM (long-chain metabolite), M (manuscript), P 
(published), S (submitted), * (shared authorship). 
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Manuscript I 
The vitamin E long-chain metabolite α-13’-COOH affects macrophage foam 
cell formation via modulation of the lipoprotein lipase system 
Stefan Kluge, Martin Schubert, Lisa Börmel, Stefan Lorkowski 
BBA Molecular and Cell Biology of Lipids 
DOI: 10.1016/j.bbalip.2021.158875 
Date of acceptance: 2nd January 2021 
 
Contribution to the manuscript 
 Concept development 
 Performance of lipoprotein isolation, RT-qPCRs, western blots, measurements of 
lipoprotein lipase activity, analysis of intracellular neutral lipid accumulation 
 Data analysis 
 Data evaluation 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 80% 
 
Key messages of manuscript I: 
The manuscript provides new insights into the regulatory role of α-T-13-COOH and its vitamin 
precursor α-TOH on VLDL-triggered foam cell formation. Both compounds affected the LPL 
system by different regulatory modes. While α-TOH mediated LPL expression via 
transcriptional regulation, α-T-13’-COOH triggered post-translational regulation of LPL via 
ANGPTL4. Further, both compounds effectively reduced catalytic activity of LPL. However, 
only α-T-13’-COOH was able to protect human THP-1 macrophages against excessive lipid 
accumulation in presence of VLDL oversupply. In addition, much higher doses of α-TOH (100 
μM) were required to preserve regulatory effects compared to α-T-13’-COOH (5 μM). 
Although their exact mode action is still unknown, our results support the concept that LCMs 
of vitamin E, including α-T-13’-COOH, represent activated and therefore functional molecules 
of their vitamin precursors. Since only α-T-13’-COOH and not α-TOH prevented excessive lipid 
accumulation in macrophages, we provide further evidence for an atheroprotective potential 
of this regulatory metabolite.  
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Manuscript II 
Simple and rapid real-time monitoring of LPL activity in vitro 
Stefan Kluge, Lisa Boermel, Martin Schubert, Stefan Lorkowski 
MethodsX (2020):7;100865 
DOI: 10.1016/j.mex.2020.100865 
Date of acceptance: 10th March 2020 
 
Contribution to the manuscript 
 Concept development 
 Performance of lipoprotein isolation, RT-qPCRs, measurements of lipoprotein lipase 
activity, analysis of intracellular neutral lipid accumulation 
 Data analysis 
 Data evaluation 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 80% 
 
Key messages of manuscript II: 
This research article provides a step-by-step protocol of a new fluorescence-based assay for 
the in vitro assessment of lipoprotein lipase activity (LPL). The assay protocol was validated by 
different experimental settings, using the well-characterized peroxisome proliferator-
activated receptor (PPAR)δ agonist GW0742 as test compound. The assay has several 
advantages over currently available in vitro LPL assays: (i) 12-well cell culture plate design for 
the simultaneous investigation of up to three different test compounds (including all assay 
controls); (ii) 24 h real-time acquisition of LPL activity data for the identification of the optimal 
timepoint for further measurements; (iii) LPL activity measurement can be complemented by 
additional cell and molecular biological analyses using the same cell samples. In our hands, 
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Manuscript III 
Long-chain metabolites of vitamin E: Interference with lipotoxicity via lipid 
droplet associated protein PLIN2 
Lisa Schmölz, Martin Schubert, Jasmin Kirschner, Stefan Kluge, Francesco Galli, Marc 
Birringer, Maria Wallert, Stefan Lorkowski 
BBA Molecular and Cell Biology of Lipids (2018):1863(8);919-927 
DOI: 10.1016/j.bbalip.2018.05.002 
Date of acceptance: 3rd May 2018 
 
Contribution to the manuscript 
 Critical evaluation of the manuscript 
 Discussion and evaluation of data/results 
 
Personal contribution to the manuscript: 5% 
 
Key messages of manuscript III: 
This research article provides evidence for a protective effect of α-LCMs against stearic acid-
induced lipotoxicity in human THP-1 macrophages. The protective effect was linked to the 
increase of lipid storage capacity at least in parts due to the induction of PLIN2 expression. In 
contrast, the vitamin precursor α-TOH induced lipotoxicity already under basal conditions 
without the addition of stearic acid. This data further strengthens the concept of a metabolic 
activation of vitamin E to functional molecules (LCMs), revealing more potent or even different 
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Manuscript IV 
The vitamin E derivative garcinoic acid from Garcinia kola nut seeds 
attenuates the inflammatory response 
Maria Wallert, Julia Bauer, Stefan Kluge, Lisa Schmölz, Yung-Chih Chen, Melanie Ziegler, 
Amy Searlea, Alexander Maxones, Martin Schubert, Maria Thürmer, Helmut Pein, Andreas 
Koeberle, Oliver Werz, Marc Birringer, Karlheinz Peter, Stefan Lorkowski 
Redox Biology (2019):24;101166 
DOI: 10.1016/j.redox.2019.101166 
Date of acceptance: 10th March 2019 
 
Contribution to the manuscript 
 Implementation of western blots 
 Data analysis 
 Data evaluation 
 Critical evaluation of the manuscript 
 
Personal contribution to the manuscript: 10% 
 
Key messages of manuscript IV: 
This research article investigated the anti-inflammatory and anti-atherogenic potential of 
garcinoic acid (δ-TE-13’-COOH), a phytochemical obtained from the seeds of garcinia kola E. 
Heckel, in LPS-activated mouse RAW264.7 macrophages and Apoe−/− mice respectively. It was 
shown that GA efficiently reduced LPS-induced inflammation via inhibition of pro-
inflammatory pathways in vitro. However, weekly administration of GA did not affect 
inflammation and atherosclerotic events in Apoe−/− mice. Hence, the promising anti-
inflammatory effects of GA observed in vitro were not reproducible in an in vivo model of 
chronic low grade inflammation.  
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Manuscript V 
α-Tocopherol preserves cardiac function by reducing oxidative stress and 
inflammation in ischemia/reperfusion injury 
Maria Wallert, Melanie Ziegler, Xiaowei Wang, Ana Maluenda, Xiaoqui Xuc, May Lin Yap, 
Roman Witt, Corey Giles, Stefan Kluge, Marcus Hortmann, Jianxiang Zhang, Peter Meikle, 
Stefan Lorkowski, Karlheinz Peter 
Redox Biology (2019):26;101292 
DOI: 10.1016/j.redox.2019.101292 
Date of acceptance: 5th August 2019 
 
Contribution to the manuscript 
 Implementation of HPLC analysis of α-tocopherol in mouse plasma  
 Data analysis 
 Data evaluation 
 Critical evaluation of the manuscript 
 
Personal contribution to the manuscript: 5% 
 
Key messages of manuscript V: 
This research article investigated the potential of an acute α-TOH administration as a new 
therapeutic strategy for the treatment of cardiac damage after myocardial infarction in a 
murine cardiac ischemia/reperfusion injury model. Administration of α-TOH significantly 
reduced infarct size, cardiac output, stroke volume and restored cardiac function. The 
observed cardioprotective effect of α-TOH was, among others, linked to decreased infiltration 
of neutrophils in the cardiac tissue as well as to reduced amounts of reactive oxygen species 
and lipid peroxidation markers within the infarcted tissue. The study provided strong evidence 
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Manuscript VI 
Garcinoic acid: A promising bioactive natural product for better 
understanding the physiological functions of tocopherol metabolites 
Stefan Kluge*, Martin Schubert*, Lisa Schmölz, Marc Birringer, Maria Wallert, Stefan 
Lorkowski 
*authors contributed equal 
Studies in Natural Products Chemistry (2016):51;435-481. 
DOI: 10.1016/B978-0-444-63932-5.00009-7 
Date of acceptance: 24th February 2016 
 
Contribution to the manuscript 
 Creation of the concept 
 Investigation and evaluation of data 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 45% 
 
Key messages of manuscript VI: 
This review article focusses on the natural sources, the chemical extraction and the biological 
effects of GA (δ-TE-13’-COOH), a natural compound of the African bitternut Garcinia kola, with 
great significance for traditional ethno medicine. The publication also attends the great 
importance of GA for in vitro and in vivo investigation of vitamin E-derived LCMs, since these 
metabolites can be generated via semi-synthesis from GA. In addition, the article provides a 
comprehensive overview about known biological functions of TOHs and TEs together with 
their respective metabolites, focusing on anti-oxidant-, anti-inflammatory and anti-
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Manuscript VII 
Long-chain metabolites of vitamin E: Metabolic activation as a general 
concept for lipid-soluble vitamins? 
Martin Schubert*, Stefan Kluge*, Lisa Schmölz, Maria Wallert, Francesco Galli, Marc 
Birringer, Stefan Lorkowski 
*authors contributed equal 
Antioxidants (2018):7(1);10 
DOI: 10.3390/antiox7010010 
Date of acceptance: 11th January 2018 
 
Contribution to the manuscript 
 Creation of the concept 
 Investigation and evaluation of data 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 45% 
 
Key messages of manuscript VII: 
This review article provides an overview about the intestinal absorption, distribution and 
metabolization of the fat-soluble vitamins A, D, E and K. Further, known biological activities of 
their respective metabolites are described under the perspective of a general concept of 
metabolic activation of fat-soluble vitamins. In the case of vitamin E, detection of vitamin E-
derived LCMs in human serum indicated a potential systemic relevance of these metabolites 
as a new class of regulatory molecules. This concept was strengthened by several studies, 
revealing anti-oxidative, anti-inflammatory, anti-carcinogenic and to some extend anti-
atherogenic effects of tocopherol-derived LCMs. Interestingly, LCMs revealed more potent 
and in part even contrary effects to their vitamin precursors. Therefore, the LCMs must be 
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Manuscript VIII 
The hepatic fate of vitamin E 
Lisa Schmölz*, Martin Schubert*, Stefan Kluge*, Marc Birringer, Maria Wallert, Stefan 
Lorkowski 
*authors contributed equal 
Vitamin E in Health and Disease (2018):1;1-30 
DOI: 10.5772/intechopen.79445 
Date of acceptance: 5th November 2018 
 
Contribution to the manuscript 
 Creation of the concept 
 Investigation and evaluation of data 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 30% 
 
Key messages of manuscript VIII: 
This review article focuses on the liver as the central organ of the human vitamin E 
homeostasis. On the one hand, the liver accomplishes the physiologic handling of vitamin E, 
including uptake, distribution, metabolism and storage. On the other hand, the liver is also a 
starting point for the modulation of vitamin E homeostasis by physiological, non-physiological 
and pathophysiological factors. As a prominent example, the neurological disorder ataxia with 
vitamin E deficiency (AVED) is linked to a mutation in the gene encoding for α-TTP, a protein 
responsible for the hepatic discrimination of α-TOH from the other forms of vitamin E. Beside 
its significance for the handling of vitamin E, the liver is also the key organ for the formation 
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Manuscript IX 
Bioactivity of vitamin E long-chain metabolites 
Stefan Kluge*, Martin Schubert*, Lisa Schmölz, Maria Wallert, Marc Birringer, Stefan 
Lorkowski 
*authors contributed equal 
Vitamin E in Human Health (2019):96;61-79 Springer Nature 
DOI: 10.1007/978-3-030-05315-4_6 
Date of acceptance: 11th March 2019 
 
Contribution to the manuscript 
 Creation of the concept 
 Investigation and evaluation of data 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 45% 
 
Key messages of manuscript IX: 
This review article focuses on the formation, distribution and regulatory properties of vitamin 
E LCMs in humans. A special focus of this article is on the description of analytical approaches 
for the detection of LCMs in human matrices. The analysis of LCMs in humans is of great 
importance to elucidate their suggested systemic relevance as a new class of signaling 
molecules. However, LCM analysis in human matrices is challenging and existing strategies for 
vitamin E analysis required further improvement to enable a reliable analysis of these 
compounds. The adaptations included an additional enzymatic deconjugation step for sample 
preparation as well as the use of more accurate techniques for sample separation and 
detection. Although the analysis of the LCMs made great progress over the last decades, 
especially the distribution of the LCMs in extrahepatic tissues beside human serum requires 
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Manuscript X 
Diversity of chromanol and chromenol structures and functions: an 
emerging class of anti-inflammatory and anti-carcinogenic agents 
Maria Wallert*, Stefan Kluge*, Martin Schubert, Andreas Koeberle, Oliver Werz, Marc 
Birringer, Stefan Lorkowski 
*authors contributed equal 
Frontiers in Pharmacology (2020):11;362 
DOI: 10.3389/fphar.2020.00362 
Date of acceptance: 10th March 2020 
 
Contribution to the manuscript 
 Creation of the concept 
 Investigation and evaluation of data 
 Drafting of the manuscript 
 
Personal contribution to the manuscript: 45% 
 
Key messages of manuscript X: 
This review article provides a comprehensive overview of the available data on signaling 
pathways involved in inflammation, apoptosis, cell proliferation and carcinogenesis of 
selected natural occurring chromanols and chromenols. Due to their ability to bind or to 
interfere with molecular targets and pathways, including 5-LO, nuclear receptors and the 
NF-κB pathway, chromanols and chromenols may represent interesting lead structures for the 
development of therapeutic approaches. Interestingly, the efficiency by which chromanols 
and chromenols exert their biological effects strongly depend on the respective regulatory 
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8 Discussion 
Driven by a small community of interested and ambitious scientist, research on vitamin E-
derived LCMs has made great progress over the last decade. Nevertheless, the LCMs still 
represent a small and underestimated area in the broad field of vitamin E research and their 
proposed significance for human health is controversially discussed. The obvious reason for 
this is the lack of convincing in vivo data confirming the promising results of various in vitro 
studies. However, the resistance of the established vitamin E community against this new 
interpretation of vitamin E function does also contribute to the ‘highly speculative’ image of 
the LCMs.  
The current research on the field is predominantly focused on the identification of 
fundamental biological functions as well as on the elucidation of potential signaling pathways 
affected by the LCMs. Only a few in vivo studies in mice have generated first insights into their 
potential physiological role. In addition, human studies on the vitamin E-derived LCMs are 
sparse and limited to the determination of their concentration in blood. Nevertheless, the 
importance of these initial in vitro and in vivo studies should not be underestimated, since 
they enabled (i) the identification of a variety of promising biological functions; (ii) generated 
hints for LCM accumulation in peripheral tissues and (iii) provided evidence for a systemic 
relevance of the vitamin E-derived LCMs in the human body. Overall, the mentioned findings 
offer promising starting points for future experiments. 
Based on the objectives mentioned in Section 5 “Aim of the thesis”, a number of central 
questions arose which were experimentally addressed in the enclosed manuscripts. Hence, 
the discussion about the contribution of these manuscripts to the scientific progress in the 
field will predominantly focus on the following research priorities (RP): 
RP1 Do potential regulatory functions of the LCMs affect crucial factors in the development 
of atherosclerosis, i.e. lipid metabolism of macrophages and inflammation? 
RP2  Which signaling pathways, i.e. receptors, signaling molecules or enzymes, are affected 
by the LCMs? 
RP3 Are there differences between the efficiency and the mediated effects of the LCMs and 
their respective vitamin precursors?   
8.1 Contribution of the integrated manuscripts to the progress of research in 
the field of vitamin E-derived LCMs 
In line with most of the recent studies in the field, the objectives of this PhD thesis are 
predominantly settled in the area of basic research. The included manuscripts can be assigned 
to two different task areas. First, the integrated review articles (manuscripts VI to X) were 
used to generate a comprehensive overview about the current knowledge on the LCMs to 
enable the identification of promising research topics and the generation of working 
hypotheses. Second, the integrated research articles (manuscripts I to IV) were used to 
DISCUSSION  247 
elucidate fundamental biological activities of the vitamin E-derived LCMs α-T-13’-COOH and 
δ-TE-13’-COOH (GA). The experiments were therefore focused on potential regulatory 
functions of the compounds on central processes in the development of atherosclerosis on 
cellular level, i.e. foam cell formation and inflammation in macrophages. In contrast, 
manuscript V presents a hitherto unknown function of α-TOH in preventing cardiac damage 
after myocardial infarction in mice, which could represent an interesting approach for the 
therapeutic application of α-TOH. Because of this important finding, the article was included 
in this PhD thesis although it does not fit with the concept that the LCMs represent the 
functional molecules of vitamin E. Hence, the contribution of manuscript V to RP1 to RP3 will 
not be discussed in the section below. A short summary of the most important progressions 
achieved with the manuscripts I to IV is provided in Figure 7.  
 
Figure 7: Personal contributions to the progress of research in the field of vitamin E-
derived LCMs. LCM (long-chain metabolite), PPARδ (peroxisome proliferator-activated 
receptor δ). 
8.1.1 Biological functions of the LCMs 
8.1.1.1 Modulation of lipid metabolism in macrophages 
The investigation of potential regulatory functions of α-T-13’-COOH in the lipid metabolism of 
macrophages was plausible for several reasons. Most importantly, recent in vivo data revealed 
that α-T-13'-COOH was selectively absorbed by murine peritoneal leukocytes, indicating a 
preferred uptake of α-T-13'-COOH into immune cells (Pein et al. 2018). Further, a previous 
investigation of our group provided first evidence for a contribution of the vitamin E-derived 
LCMs in lipid metabolism, showing that α-T-13’-COOH enhanced the expression of CD36. 
Surprisingly, the regulation of CD36 had no influence on oxLDL uptake, on the contrary, oxLDL 
uptake was even diminished by α-T-13’-COOH (Wallert et al. 2014b). Based on these promising 
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results, manuscript III (under my collaboration) investigated the regulatory effect of α-T-13’-
COOH on the expression of PLIN2 – a central mediator of intracellular lipid storage – in human 
THP-1 macrophages. The investigation showed that α-T-13’-COOH enhanced the expression 
of PLIN2, which at least in parts protected human THP-1 macrophages from stearic acid 
induced lipotoxicity (Schmölz et al. 2018). In addition, results from large-scale epidemiological 
studies provided also evidence for a casual association between TRLs, i.e. chylomicrons and 
VLDL, with macrophage foam cell formation and atherosclerosis. Thus, manuscript I expanded 
the existing knowledge by the investigation of regulatory effects of α-T-13’-COOH on the 
expression of LPL – a key enzyme of cellular free-fatty acid (FFA) supply – as well as its 
physiological regulator ANGPTL4. Interestingly, α-T-13’-COOH did not affect the expression of 
Lpl, but strongly induced the expression of Angptl4. In line with this, α-T-13’-COOH efficiently 
reduced the enzymatic activity of LPL and was therefore able to protect human THP-1 
macrophages against excessive lipid accumulation in presence of VLDL oversupply. To enable 
the determination of neutral lipids and LPL activity in the same cell sample, it was necessary 
to develop a new methodical approach for a cell culture based real-time fluorescence assay. 
The method details are explained in manuscript II. To complete the regulatory picture of the 
LCMs on mechanism involved in macrophage foam cell formation, a running project of our 
group is currently investigating the effects of α-T-13’-COOH on cellular cholesterol export via 
ABCA1. 
Taken together, the discovered biological activities provide strong evidence for a regulatory 
role of α-T-13’-COOH in different areas of macrophage foam cell formation, i.e. lipid uptake 
(via CD36 and the LPL system), lipid storage (via PLIN2) and probably lipid export (via ABCA1). 
Therefore, the contribution of the included manuscripts (created by the author or with his 
collaboration) to RP1 can be described as follows:  
(i)  The discovery of two additional biological functions of α-T-13’-COOH, i.e. the ANGPTL4-
mediated regulation of neutral lipid import and the PLIN2 mediated regulation of lipid 
storage, significantly improved the existing knowledge about a regulatory role of the 
LCMs in the lipid metabolism of macrophages.  
(ii)  The development of a simple and rapid in vitro assay for the comprehensive investigation 
of the LPL system provides a methodical platform for future studies on the LCMs or any 
other promising compound.  
(iii)  The linkage of the studies mentioned above together with first impressions from the 
ongoing project on ABCA1 yield a detailed picture of the regulatory role of α-T-13’-COOH 
in different key mechanism of macrophage foam cell formation. We therefore 
hypothesize that α-T-13’-COOH could probably also affect the complex development of 
atherosclerosis in vivo. If so, results of the manuscripts I and III, along with the previous 
data of Wallert et al. (Wallert et al. 2014b) would indicate an atheroprotective potential 
of α-T-13’-COOH. 
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8.1.1.2 Modulation of the inflammatory processes  
Anti-inflammatory activities are by far the most well investigated part of the LCM function. To 
date, anti-inflammatory activities of various LCMs have been shown in different in vitro and in 
vivo models (the reader is referred to Section 3.3.1 “Anti-inflammatory activit”). In these 
studies, enzymes, such as iNOS, COX-2 and 5-LO, as well as pro-inflammatory factors, like pro-
IL-1β, IL-6 and TNF-α, appeared as major targets for the anti-inflammatory function of vitamin 
E-derived LCMs (Wallert et al. 2020). Since inflammation also represents a crucial factor in the 
development of atherosclerosis, anti-inflammatory effects of α- and δ-LCMs were investigated 
in different types of macrophages (Wallert et al. 2015; Schmölz et al. 2017; Pein et al. 2018).  
The contribution of the anti-inflammatory activity of vitamin E-derived LCMs to their proposed 
systemic relevance is a central topic of our group. Besides their physiological significance, we 
are also interested in the potential use of LCMs for therapeutic applications and drug 
development. Unfortunately, this kind of investigations required access to large amounts of 
the compounds in high purity. To date, most of the prominent vitamin E-derived LCMs, such 
as α-T-13’-COOH, are not commercially available and must be produced via chemical 
synthesis. Thus, they do not represent preferred candidates for therapeutic applications so 
far. However, a common method for drug development is the use of bioactive natural 
compounds. Interestingly, the seeds of Garcinia kola E. Heckel, a plant still used in African 
ethno medicine, contains high amounts of δ-TE-13’-COOH the so called G. Previous studies on 
pure GA or extracts from the seeds of Garcinia kola E. Heckel already revealed anti-oxidative 
(Terashima et al. 2002) and anti-proliferative (Mazzini et al. 2009) functions of this promising 
natural compound. Therefore, manuscript IV (with my collaboration) focused on the 
investigation of anti-inflammatory effects of GA as well as on an optimization of GA extraction 
and purification from garcinia kola seeds. First, the efficiency of GA isolation was increased by 
6.6-fold compared to already existing protocols. Second, GA reduced the expression of iNOS, 
COX-2, pro-IL-1β, IL-6 and TNF-α as well as the formation of their respective products, i.e. nitric 
oxide, PGE2, and TXB2, in LPS-stimulated murine RAW264.7 macrophages. In contrast, 
intraperitoneal application of GA to Apoe−/− mice did not affect inflammatory processes during 
atherogenesis. Thus, GA seems to be an efficient treatment for acute high-grade 
inflammation, while it has no effect on chronic low-grade inflammation. The observed anti-
inflammatory potential of δ-TE-13’-COOH in vitro was confirmed by a simultaneous 
investigation of a collaborating group, where GA (300 nM) efficiently inhibited PGE2 formation 
in LPS-stimulated monocytes as well as the activity of isolated 5-LO (Pein et al. 2018).  
In summary, manuscript IV together with the results of Pein et al. provide evidence for a very 
potent ant-inflammatory activity of δ-TE-13’-COOH, among others in macrophages. Further, 
GA could probably serve as an efficient treatment of acute high-grade inflammation. The 
contribution of manuscript IV (under my collaboration) to RP1 can be described as follows: 
(i)  The discovery of an anti-inflammatory function of δ-TE-13’-COOH in murine RAW264.7 
macrophages significantly expanded the existing knowledge about the biological activities 
of this promising natural compound and provided evidence for its potential use for 
pharmacological applications.  
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(ii)  The significant improvement of existing protocols for the extraction and isolation of GA 
from the seeds of Garcinia kola E. Heckel enabled a facilitated access to large amounts of 
δ-TE-13’-COOH in high purity, paving the way for its potential use in drug development.  
(iii) The observation that GA revealed no effect on chronic low-grade inflammation in 
atherosclerotic mice indicated that although GA represents a potent anti-inflammatory 
compound, other LCMs (α-T-13’-COOH) are probably more potent in vivo (separately 
discussed in Section 8.2.3 “Utilized compounds”). 
8.1.2 Affected signaling pathways 
Although various biological activities of vitamin E-derived LCMs have been described so far, 
almost nothing is known about the signaling pathways involved in their regulatory function. 
In a study on the structure-function relationship of different LCMs, scientists of our group 
revealed that the effects of the LCMs depend on the presence of their complete molecular 
structure, i.e. chromanol ring system, modified side‐chain and functional groups (-OH or -
COOH). It was shown that only the LCMs but not their vitamin precursors and other 
compounds, i.e. α-CEHC mimicking the chromanol ring system and pristanic acid imitating the 
modified side chain, exert specific and distinct effects on the expression of iNOS and CD36. 
Thus, Schmölz et al. suggested the presence of a receptor or a specific signaling pathway 
mediating LCM function. In line with this hypothesis, Podszun et al. described an interaction 
of α-T-13’-COOH with the nuclear receptor PXR. In their study, α-T-13’-COOH increased the 
activity of PXR (in a reporter gene assay) as well as the expression of the PXR target gene P-gp 
in human epithelial-like colon LS180 cells. As a further prove for the interaction of vitamin E-
derived LCMs with PXR, a recent preprint showed that PXR activity is also increased by GA 
(Bartolini et al. 2020). 
The elucidation of potential signaling pathways mediating the regulatory function of α-T-13’-
COOH on the lipid homeostasis of human THP-1 macrophages was also included in manuscript 
I. Since ANGPTL4 represents a well-known target gene of PPARδ (Makoveichuk et al. 2012) – 
the predominant PPAR form in human THP-1 macrophages (Vosper et al. 2001) – the PPARδ 
antagonist GSK3787 was used to investigate whether the nuclear receptor was involved in the 
induction of Angptl4 expression by α-T-13’-COOH. Indeed, co-incubation of α-T-13’-COOH and 
GSK3787 significantly reduced the induction of Angptl4 expression, indicating that the gene 
regulatory function of α-T-13’-COOH is probably mediated by PPARs. This concept seems to 
be plausible, since other studies also observed an induction of PPAR target genes, such as Plin2 
and Cd36, by α-T-13’-COOH (Wallert et al. 2014b; Schmölz et al. 2018). However, inhibition of 
PPARδ had no effect on functional study parameters, i.e. LPL activity and intracellular lipid 
accumulation. We therefore concluded that the regulatory effects of α-T-13’-COOH might not 
only result from a specific interaction with a single nuclear receptor.  
In summary, manuscript I together with the results of previous studies provide first hints for 
an interaction of α-T-13’-COOH and other vitamin E LCMs with nuclear receptors, such as PXR 
and PPARs. Nevertheless, further experiments are necessary to fully unravel the regulatory 
pathways. The contribution of manuscript I to RP2 can be described as follows: 
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(i)  Manuscript I provides the first description of a causal connection between the inhibition 
of PPARδ and the subsequent interference with the regulatory effect of α-T-13’-COOH on 
the PPAR target gene Angptl4.  
(ii)  The discovery of a potential mediation of the gene regulatory function of α-T-13’-COOH 
by PPARs generates new starting points for future investigations on LCM signaling.  
8.1.3 Functional comparison of metabolites and vitamin precursor 
Most of the studies on biological activities of vitamin E-derived LCMs also considered the 
question, whether the LCMs reveal more potent or even different effects than their vitamin 
precursors. Indeed, differences in potency and modes of action between the two compound 
classes were discovered for all areas of their known functional spectrum, i.e. anti-
inflammatory effects (Wallert et al. 2015; Schmölz et al. 2017), anti-carcinogenic effects 
(Birringer et al. 2010), regulation of lipid metabolism (Wallert et al. 2014b), interaction with 
pharmaceuticals (Podszun et al. 2017) and regulation of vitamin E metabolism (Torquato et al. 
2016a). The key findings of these investigations can be summarized as follows: (i) The potency 
of the LCMs is generally higher than the potency of their vitamin precursors, i.e. significantly 
lower concentrations of the LCMs are required to reveal regulatory effects. (ii) The 13’-COOH 
metabolites represent the most potent compounds within the group of vitamin E LCMs. (iii) 
The LCMs revealed different modes of action compared to their metabolic precursors.  
The manuscripts I and III also considered potential differences between efficiency or 
functionality of α-T-13’-COOH and α-TOH on two new aspects in the regulation of cellular lipid 
homeostasis. The results of both manuscripts confirmed that significantly lower 
concentrations of α-T-13’-COOH (5 μM) were required for the regulation of the investigated 
target genes, i.e. Angptl4, Lpl and Plin2, compared with α-TOH (100 μM). In addition, 
manuscript I revealed that α-T-13’-COOH was able to protect human THP-1 macrophages 
against excessive lipid accumulation in the presence of VLDL oversupply, while α-TOH had no 
effect. In line with this, manuscript III showed that α-T-13’-COOH damped the negative impact 
of stearic acid induced lipotoxicity on cell viability of THP-1 macrophages, while α-TOH even 
increased the cytotoxic effects. Hence, both investigations provided evidence for functional 
differences in the regulation of the cellular lipid homeostasis between the LCMs and their 
vitamin precursors. The contribution of the manuscripts I and III to RP3 can be described as 
follows: 
(i)  The description of differences concerning potency and function of α-TOH and α-T-13’-
COOH in two hitherto unknown aspects of the cellular lipid homeostasis represent a 
useful expansion to the already existing knowledge on the topic.   
(ii)  The results of the manuscripts I and III further strengthened the concept that the LCMs 
represent activated and therefore functional molecules of their vitamin precursors. 
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8.2 Limitations of current LCM research 
The following section will discuss general limitations of the current LCM research as well as 
specific limitations of the included manuscripts. A short summary of the most important 
limitations is provided in Figure 8.  
 
Figure 8: Schematic overview about major limitations of current LCM research. LCM (long-
chain metabolite). 
8.2.1 Utilized experimental models 
The choice of a suitable experimental model generally depends on the respective research 
objectives. In case of the vitamin E LCMs, current research is predominantly focused on the 
elucidation of biological functions in vitro, while the in vivo situation plays only a subordinate 
role (Kluge et al. 2019). This corresponds to the frequency of use of in vitro and in vivo models 
in the currently available studies on vitamin E-derived LCMs. Here, cell culture studies 
represent the predominant test system, while in vivo models are poorly used.  
The majority of investigations on the LCMs intend to unravel toxic effects, biochemical 
processes, regulatory functions and differences between the potency of the metabolites. 
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Hence, cell culture models are used to enable the simplified investigation of specific aspects 
of the LCM function. In addition, a systemic relevance of the LCMs in the human body was also 
suggested. However, the complex test environment for the appropriate investigation of 
potential systemic effects is difficult to imitate in vitro. Hence, suitable in vivo models are 
required to investigate the hepatic metabolisation, body distribution and potential 
physiologically relevant functions of the LCMs. 
8.2.1.1 In vitro models  
The term ‘in vitro model’ represents a collective term for established cell lines, primary cells 
or stem cells that offer a controlled experimental environment (Alberio et al. 2012). To date, 
various in vitro models, such as human HepG2 liver cancer cells, human THP-1 macrophage-
like cells, human HT-29 colorectal adenocarcinoma cells, human HTC 116 colon carcinoma 
cells, human epithelial-like-colon LS180 cells or murine RAW264.7 macrophages, were used 
to investigate different functional aspects of the LCMs (Schubert et al. 2018; Wallert et al. 
2020). Cellular models are the instrument of choice for the initial characterization of new 
compounds, because they allow the transfer of complex physiological or pathophysiological 
processes to simpler molecular ones. Given that the current state of research on vitamin E-
derived LCMs is still on the level of basic research, in vitro models are useful tools for the 
generation of preliminary data for more profound investigations. In more detail, cells provide 
several advantages, such as the ability for a direct exposure to the LCMs; controlled 
environmental conditions; the ability to augment, block or modulate different cell responses; 
and the ability to measure cell responses in absence of vitamin E metabolism (Alberio et al. 
2012). Nevertheless, the in vitro models cannot cover the complex biochemical, physiological 
or metabolic processes affecting LCM functionality in living organisms. Hence, transferability 
of results generated in vitro to the in vivo situation is still a matter of debate. Beside this 
obvious limitation, in vitro models provide further disadvantages, such as the influence of 
chemical properties on the bioavailability of the applied LCMs, i.e. solubility, volatility and 
precipitation, or chemical interactions altering the culture conditions, i.e. pH, osmolarity, 
protein binding (Nesslany 2017). 
The manuscripts I to IV are based on different in vitro models, which have the advantages and 
disadvantages mentioned above. In these studies, the experiments are focused on the 
investigation of regulatory functions of the LCMs on key factors in the pathogenesis of 
atherosclerosis, i.e. foam cell formation and inflammation. For this kind of experiments, the 
use of primary human cells as an ex vivo model is considered as the gold standard. For 
example, Pein et al. used primary polymorphonuclear leukocytes  (PMNL) and peripheral 
blood mononuclear cells (PBMC) to simulate human-like conditions for the investigation of 
immunomodulatory functions of α-T-13’-COOH (Pein et al. 2018). However, human primary 
cells are difficult to handle and their availability is often limited. Therefore, the human-derived 
leukemia monocytic cell line THP-1 was used for the experiments of the manuscripts I – III. 
This cell line is commonly used as a replacement of human PBMCs and can easily be 
differentiated to macrophage-like cells by treatment with phorbol-12-myristate-13-acetate 
(PMA) (Bosshart und Heinzelmann 2016). Nevertheless, THP-1 cells cannot be completely 
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equated with PBMCs since both cells revealed differences concerning the degree of gene 
expression (basal and after stimulation) and the secretion of cytokines. For example, PBMCs 
show a significantly higher LPS responsiveness compared with THP-1 monocytes, making THP-
1 cells a poor replacement model for the investigation of inflammatory response in humans 
(Chanput et al. 2014). However, none of the described differences between PBMCs and THP-
1 cells interferes with the investigated parameters of the manuscripts I to III. Further, the same 
in vitro model was used for a previous study on the regulatory effects of α-T-13’-COOH on 
macrophage foam cell formation (Wallert et al. 2014b). In my opinion, it was therefore 
justified to use THP-1 macrophages as an established experimental model that at least in parts 
allows conclusions to the in vivo situation. In addition, THP-1 macrophages also provide 
several advantages over PBMCs, such as a higher doubling rate, long culture times (25 
passages) without changes in cell sensitivity and activity as well as a low variability in the cell 
phenotype because of the homogeneous genetic background (Chanput et al. 2014).  
Manuscript IV investigated the anti-inflammatory effects of GA (δ-TE-13’-COOH) in presence 
of a LPS stimulus. Therefore, the in vitro model had to be switched from human THP-1 
macrophage-like cells to murine RAW264.7 macrophages for several reasons: (i) As already 
mentioned, human THP-1 macrophages represent a poor in vitro model for the investigation 
of LPS response (Chanput et al. 2014). (ii) Human macrophages do not express functional iNOS 
(Gross et al. 2014), which represented a central investigation target of manuscript IV. (iii) The 
in vitro model should be used for the generation of preliminary data for a subsequent 
investigation in mice. Hence, the utilized in vitro model should predominantly allow for 
drawing conclusions to the in vivo situation in mice. Murine RAW264.7 macrophages 
represent an established cell line that is commonly used for the investigation of anti-
inflammatory effects of various compounds against a LPS stimulus (Kumar R und Abraham 
2017; Lee et al. 2016). Therefore, the use of RAW264.7 macrophages seemed reasonable, 
since previous studies of our group also relied on this model (Wallert et al. 2015).  
8.2.1.2 In vivo models  
In vivo models, such as mice, rats, hamsters or rabbits, represent the preferred tool to 
generate deeper insights into the interactions of a test compound with a complex physiologic 
environment. This does among others include the provision of information about interactions 
with the xenobiotic metabolism as well as on interactions between different cell types or 
tissues (Tice et al. 2013). Nevertheless, the use of animals as a model for human physiology is 
not without controversy, since especially rodents – the most frequently used in vivo models – 
show remarkable physiological and genetic differences to humans. Thus, transferability of 
data generated in these models to the physiological situation in humans is always a matter of 
debate (Perlman 2016; Shanks et al. 2009). However, in vivo models are of special interest for 
LCM research, since the metabolites are physiologically formed in the liver. Different 
investigations concerning the determination of LCM blood concentrations in humans already 
provided evidence for a systemic relevance of these compounds (Wallert et al. 2014b; Ciffolilli 
et al. 2015; Giusepponi et al. 2017), i.e. the metabolites may be transferred to peripheral 
tissues where they probably serve as regulatory molecules (Schubert et al. 2018). 
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Interestingly, the hepatic metabolism of vitamin E in rodents is very similar to the one in 
humans, making them a good model to investigate physiologic effects of the vitamin E LCMs 
(Wallert 2014a). 
Current in vivo studies on vitamin E-derived LCMs are predominantly focused on the impact 
of specific functional aspects (discovered in vitro) on the development and the progression of 
different diseases. Hence, the used in vivo models are not specifically designed for vitamin E 
research and rather represent established and reliable models of human diseases with an 
assumed connection to one or more of the discovered LCM functions. In addition, the sparse 
knowledge on the LCM physiology, e.g. rate of metabolic elimination, further complicates the 
choice of a suitable test compound, the form of compound administration and the sufficient 
dosage of the compounds. In manuscript IV used Apoe−/− mice were used to investigate the 
impact of GA (δ-TE-13’-COOH) on the progression of atherosclerosis. The mice received 1 mg 
GA/kg body weight via weekly intraperitoneal injection. Surprisingly, administration of GA had 
no effect on inflammation during atherogenesis (Wallert et al. 2019). The authors concluded 
that a model of chronic low-level inflammation, such as atherosclerotic mice, might not be the 
optimal test system for the pharmacological application of GA. However, it cannot be excluded 
that factors such as the form of compound administration as well as metabolic elimination of 
GA biased their results. With respect to these limitations, a recent study provided potential 
starting points for the improvement of future in vivo investigations. Based on their previous 
in vitro data, Pein et al. investigated the inhibitory effect α-T-13’-COOH and δ-TE-13’-COOH 
on 5-LO activity in a zymosan-induced peritonitis model. For this, CD-1 mice received 10 mg/kg 
of either α-T-13’-COOH or δ-TE-13’-COOH via intraperitoneal injection. Surprisingly, only α-T-
13’-COOH but not δ-TE-13’-COOH inhibited 5-LO product formation in leukocytes isolated 
from exudates, although each compound had efficiently blocked 5-LO product formation in 
vitro. These results for the first time indicated that the form of the administrated LCMs could 
influence the experimental outcomes in vivo (separately discussed in Section 8.2.3 “Utilized 
compounds”). In addition, another group of mice received 50 mg α-TOH/kg body weight via 
perioral administration, representing a more physiologically approach of compound 
administration compared with direct intraperitoneal injection. Despite of this indirect 
administration, ultra-performance liquid chromatography ESI tandem mass spectrometry 
analysis revealed that α-T-13’-COOH was accumulated in leukocytes isolated from exudates. 
This results for the first time indicated that orally administrated α-TOH is metabolized to α-T-
13’-COOH in the liver, which is subsequently transferred to peripheral immune cells (Pein et 
al. 2018). Hence, oral administration of the vitamin precursors could be used for a better 
simulation of the physiologic situation in future in vivo investigations, at least for α-T-13’-
COOH. 
In summary, the amount of available data on the physiology of vitamin E LCMs is still too small 
to generate a final blue print for the optimal design of in vivo experiments. However, the 
comparison of both in vivo studies mentioned above provides important findings for the 
improvement of future in vivo investigations. (i) There is evidence for a selective physiological 
relevance of the α-LCMs, which should be taken into account for the choice of test 
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compounds. (ii) The possibility of a quick metabolic elimination of the test compounds must 
be considered for their administration and their dosage. (iii) The relevance of available in vitro 
data for future in vivo investigations should be carefully reevaluated based on the new insights 
from both investigations.  
8.2.2 Dosage and uptake of the LCMs 
Dosage and uptake of the administered LCMs are two important experimental factors with 
major influence on the accuracy of data generated by in vitro and in vivo investigations. 
Because most of the currently available studies on the LCMs (including manuscripts I and III) 
are based on cell culture models, the following section will predominantly discuss the 
significance of LCM dosage and uptake for in vitro experiments. Nevertheless, both factors are 
also important for in vivo investigations.  
One of the major aims of LCM research is to proof the suggested physiologically relevance of 
the compounds. In theory, determination of physiologic LCM concentrations in cells and 
tissues of the human body would provide important reference values for the correct dosage 
of the metabolites in vitro. However, low nanomolar concentrations determined in human 
blood represented the only reference for the assessment of suitable LCM concentrations for 
in vitro experiments until recently (Wallert et al. 2014b; Giusepponi et al. 2017). For example, 
the mean α-T-13’-COOH plasma concentration of ten healthy volunteers was determined 
between 26.2 ± 13.9 nM (Pein et al. 2018). In contrast, most of the current in vitro studies 
(including manuscripts I and III) used a α-T-13’-COOH concentration of 5 μM, i.e. a 
supraphysiologic concentration in relation to nanomolar blood levels. The use of 
supraphysiologic concentrations might represent a common practice for the elucidation of 
general modes of action of the LCMs, but is in conflict with the proposed physiological 
relevance of the metabolites. This example illustrates an often-criticized issue in LCM research 
that is expanded by the lack of data on the cellular uptake of the metabolites. However, this 
criticism is not fully justified, because current in vitro investigations (including manuscripts I 
and III) did not attempt to imitate the physiologic environment of human blood rather of 
specific human cells or tissues, such as macrophages or the liver (Birringer et al. 2010; Wallert 
et al. 2014b; Schmölz et al. 2018). Thus, human blood may therefore not represent the optimal 
reference matrix for the evaluation of LCM concentrations.  
Interestingly, a recent study in mice addressed most of the issues mentioned above. Under 
basal conditions, murine plasma levels of α-T-13’-COOH (10 - 35 nM) were comparable to the 
plasma levels in humans (8 - 49 nM) (Pein et al. 2018). Surprisingly, oral application of 50 mg 
α-TOH/kg body weight had no influence on α-T-13’-COOH plasma concentration, but 
significantly increased the concentration of the metabolite in exudates (basal: 150 nM; α-TOH 
treatment: 230 nM) and peritoneal leukocytes isolated from these exudates (basal: 5 nM; α-
TOH treatment: 10 - 20 nM). Further, parallel ingestion of α-TOH (50 mg/kg body weight) and 
sesamin – a known inhibitor of hepatic vitamin E catabolism that blocks CYP4F2/CYP3A4-
dependent ω-hydroxylation – only decreased α-T-13’-COOH levels in plasma, while the 
concentration in exudates remained unchanged (Pein et al. 2018). These results indicate that 
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blood seems only to serves as a transport matrix for α-T-13’-COOH, while higher amounts of 
the metabolite accumulate at its potential sites of actions, e.g. immune cells. These peripheral 
long-term stores are only subjected to slight fluctuations and can be increased by the 
additional administration of α-TOH. Since the physiologic environment of rodents differs from 
that of humans, Pein et al. also proofed their findings in a human matrix, i.e. PMNLs isolated 
from human blood. Interestingly, the basal concentration of α-T-13’-COOH in PMNLs was 
already on micromolar level (Pein et al. 2018). These results showed that human peripheral 
cells can accumulate α-T-13’-COOH in significantly higher amounts compared with the low 
nanomolar levels in blood. In addition, incubation of the PMNLs with 150 nM α-T-13’-COOH 
for 20 minutes significantly enhanced the intracellular concentration of the metabolite (up to 
50 μM), indicating a highly efficient uptake of α-T-13’-COOH.  
Taken together the study of Pein et al. provides several important findings that should be 
considered for the assessment and discussion of LCM concentrations in current in vitro 
experiments. First, the LCM blood levels represent a poor reference to derive suitable 
concentrations for in vitro experiments, since peripheral cells and tissues seem to accumulate 
higher amounts of the LCMs (up to 50 μM of α-T-13’-COOH in human PMNLs). Hence, the LCM 
concentrations used for current in vitro investigations (including manuscripts I and III) would 
approximately correspond to the physiological situation, at least for α-T-13’-COOH. However, 
the studies in manuscripts I and III were carried out in human THP-1 macrophages-like cells. 
Therefore, the determination of α-T-13’-COOH levels in human PBMCs would also be of 
interest for a more accurate assessment of the physiologic α-T-13’-COOH concentration in 
macrophages. Second, the results of Pein et al. indicate a highly efficient uptake of α-T-13’-
COOH into PMNLs. However, uptake kinetics could also differ between primary cells and cell 
lines. Experiments of our group (unpublished data) generated a first impression on the uptake 
of α-T-13’-COOH into human THP-1 like macrophages. After 24 h incubation with 5 μM α-T-
13’-COOH, the THP-1 macrophages revealed an intracellular concentration of 4 μM of the 
compound. These results provide evidence for the uptake of α-T-13’-COOH into THP-1 
macrophages, although uptake efficiency was significantly lower compared with human 
PMNLs. Nevertheless, after an incubation time of 24 h (like in most in vitro experiments, 
including that in manuscripts I and III) nearly the complete amount of the administrated α-T-
13’-COOH could be detected inside the cell. Third, the findings of Pein et al. should be used as 
a starting point for the establishment of a general database for LCM concentrations in cells, 
tissues and other matrices with relevance for the LCM function in vivo. Broad knowledge on 
the distribution of the LCMs as well as on their concentration in different in vivo matrices could 
also improve the accuracy and significance of in vitro investigations on physiologically relevant 
LCM functions. Based on our current knowledge on vitamin E storage, metabolisation and 
accumulation, an initial determination of α-T-13’-COOH concentrations in adipose tissue and 
muscle (Bjørneboe et al. 1990), liver (Bardowell et al. 2012a), heart (Mustacich et al. 2007) 
and brain (Fukui et al. 2015) could be of interest.  
DISCUSSION  258 
8.2.3 Utilized compounds 
In general, experiments concerning the biological activity of certain compounds highly depend 
on their purity to ensure that potential effects are contributed to the compound itself and not 
to side products or contaminations. The vitamin E-derived LCMs (at least the α- and δ-forms) 
are generated via semi-synthesis from GA (δ-TE-13’-COOH) and thus their purity must be 
confirmed by GC-MS or HPLC-MS analysis. The purity of the synthesized LCMs used for in vitro 
studies (including that in manuscripts I, III and IV) was determined as > 95% (Birringer et al. 
2010; Schmölz et al. 2017) and does therefore meet the quality requirements for 
pharmaceutical compounds (Singh et al. 2018). In addition, isolated GA was characterized as 
enantiopure, providing optimal chemical conditions for the semi-synthesis of α- and δ-LCMs  
(Mazzini et al. 2009). Nevertheless, both LCM forms are obtained as a racemic mixture after 
their semi-synthesis from GA (unpublished data). This is in contrast to natural vitamin E forms 
that occur as a single enantiomer (Brigelius-Flohé und Traber 1999). In turn, natural vitamin 
E-derived LCMs are also considered to be present as one enantiomeric form, indicating that 
the use of synthetic LCMs for in vitro experiments would not correspond to the physiologic 
situation in humans. However, given that the observed biological effects of the LCMs in vitro 
are probably only attributed to one enantiomeric form, significantly lower concentrations of 
the relevant enantiomer would be necessary to mediate the observed regulatory effects. 
Unfortunately, no synthetic approach for the enantiopure synthesis of the respective LCMs is 
currently existing and it is therefore not possible to prove this hypothesis. Interestingly, a 
recent analysis of α-T-13’-COOH serum concentrations of healthy volunteers who received 
1000 IU RRR-α-TOH per day (for one week), revealed three hitherto unknown compounds with 
identical masses like α-T-13’-COOH. Additional characterization by high-resolution mass 
spectrometry revealed that these compounds are potential isomers of α-T-13’-COOH. Hence, 
α-T-13’-COOH blood concentrations are probably detected as a bulk parameter comprised of 
different isomers (Giusepponi et al. 2017).  
Another general issue concerning form and shape of probably all vitamin E-derived LCMs is 
their chemical modification. Enzymatic conjugation, i.e. sulfation and glucuronidation (Freiser 
und Jiang 2009; Zhao et al. 2010), of the LCMs occurs during the hepatic metabolism of vitamin 
E and seems to be therefore of relevance for in vivo studies. In contrast, the synthetic LCMs 
used for the majority of in vitro studies (including manuscripts I and III) are unconjugated. 
Investigations in human blood revealed that α-T-13’-COOH and α-T-13’-OH physiologically 
occur in their conjugated form, i.e. as sulfated or glucuronidated conjugates (Wallert et al. 
2014b; Ciffolilli et al. 2015; Giusepponi et al. 2017). Interestingly, conjugates of γ- and δ-
metabolites were also detected in A549 cells, a cell line that is able to generate vitamin E-
derived LCMs via endogenous synthesis (Jiang 2007). Thus, modification of the LCMs seems 
also to occur in several cell culture models. So far, no comparable results have been described 
for THP-1 like macrophages, indicating that enzymatic conjugation had no influence on the in 
vitro experiments included in manuscripts I and III. Nevertheless, enzymatic modification of 
the metabolites could represent an important factor that needs to be considered for future 
experiments, especially since Jiang et al. provided evidence that the sulfated metabolites do 
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not reveal biological activity (Jiang 2008). Hence, synthetic LCMs used for in vitro investigation 
would always be present in their active (unconjugated) form, while the majority of 
physiologically LCMs in vivo is comprised of inactive conjugates. If this holds true, the 
transferability of results concerning the biological activity of LCMs in vitro to the physiological 
situation in vivo would be even more complicated.  
Beside these general factors affecting all LCM forms, individual differences between the 
compounds are also of interest. To date, a variety of biological activities for different forms of 
vitamin E-derived LCMs was described. Here, especially the efficacy appeared to differ 
between the compounds. Although none of the currently available studies directly compared 
the efficacy of all LCM forms, the entirety of in vitro investigations allows for derivation of 
general structure specific aspects of the LCM function. First, the 13’-COOH metabolites seem 
to represent the most potent forms among the group of vitamin E-derived LCMs (Wallert et 
al. 2014b; Schmölz et al. 2017; Wallert et al. 2015; Birringer et al. 2010). Second, there are a 
few hints that TE-derived metabolites act more potent than the TOH-derived metabolites, at 
least in cell lines or cell free experimental models (Wallert et al. 2019; Pein et al. 2018). Third, 
methylation pattern of the chromanol ring of the different LCM forms is probably not as 
relevant for their effectiveness as it is for their TOH or TE precursors (Schmölz et al. 2017). 
Interestingly, potency of the different LCM forms seems also to depend on the utilized test 
system. This topic was recently addressed by an investigation comparing the ability of α-T-13’-
COOH and δ-TE-13’-COOH to inhibit 5-LO activity in different experimental models. Initially, 
the activity of human recombinant 5-LO (pure cell-free enzyme) was inhibited by δ-TE-13’-
COOH at an IC50 of 35 nM, while almost ten times of the amount was necessary for α-T-13’-
COOH (IC50 270 nM). However, analysis of 5-LO activity in primary human PMNLs revealed 
contrary results. Here, α-T-13’-COOH (300 nM) reduced 5-LO product formation by 80%, while 
δ-TE-13’-COOH (300 nM) only reached a blocking rate of 50%. These results were confirmed 
in a murine zymosan-induced periodontitis model, where mice were treated (i.p.) with 10 
mg/kg body weight of both compounds. Interestingly, only α-T-13’-COOH and not δ-TE-13’-
COOH reduced 5-LO product formation in vivo, which was verified by the detection of reduced 
amounts of 5-LO products (e.g. LTC4) in exudates. Additional experiments revealed that both, 
primary human PMNLs and peritoneal leukocytes isolated from murine exudates, 
accumulated significantly higher amounts of α-T-13’-COOH, while the amounts of δ-TE-13’-
COOH was substantially lower (PMNLs) or even not detectable (peritoneal leukocytes). The 
authors concluded that the high inhibitory potential of α-T-13’-COOH on 5-LO activity ex vivo 
and in vivo was linked to the efficient uptake and specific accumulation of the compound in 
primary human PMNLs and peritoneal leukocytes compared with the less efficient uptake by 
or complete absence of δ-TE-13’-COOH in their cells. The results further indicate that although 
multiple LCMs (including δ-TE-13′-COOH) were able to inhibit 5-LO, only α-T-13′-COOH seems 
to be relevant for systemic effects in vivo. It can therefore be speculated, whether α-T-13’-
COOH (key study target of manuscripts I and III) may represent the only suitable LCM for future 
in vitro and in vivo investigations on the potential systematic relevance of the vitamin E 
metabolites. 
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8.2.4 Modes of action 
The elucidation of the exact modes of action underlying the biological effects of vitamin E-
derived LCMs represents a central priority of current LCM research, as well as a crucial 
requirement for future scientific progress on the field. However, the origin of the question 
concerning the existence of specific regulatory pathways triggered by vitamin E or its 
metabolites already goes back to the initial discovery of gene regulatory functions of α-TOH 
in 1988 (Mahoney und Azzi 1988). Since then, various biological activities of the LCMs have 
been described, but still almost nothing is known about their exact modes of action. 
Nevertheless, especially specific gene regulatory effects of α-T-13’-COOH, i.e. regulation of 
iNos-, Cox-2-, Cd36-, Plin2-, Angptl4- and Il-expression, provided useful hints on the potential 
involvement of central signaling pathways linked to these target genes (manuscripts I and III; 
(Wallert et al. 2014b; Wallert et al. 2015)). Further, a recent in vitro study was intended to 
identify the parts of the LCM molecule that are relevant for the mediation of the observed 
regulatory functions. The study revealed that the combination of three structural elements of 
the LCM molecule, i.e. chromanol ring, aliphatic side chain and functional hydroxylic- or 
carboxylic group, seems necessary to exert gene regulatory functions. In contrast, a single-, 
i.e. α-CEHC (chromanol ring) and pristanic acid (side chain), or the combination of only two 
structural elements of the molecule, i.e. α-TOH and δ-TOH (missing functional group), were 
not sufficient. Based on these results, Schmölz et al. suggested the existence of a receptor or 
specific signaling pathways mediating LCM functions (Schmölz et al. 2017).  
If this concept holds true, three different options seem conceivable (The following hypotheses 
are be based on the current knowledge on α-T-13’-COOH, since almost nothing is known about 
the other LCMs). First, a peripheral or integral receptor located at the cell surface or within 
the membrane may exists that binds the LCMs and mediates further signaling. This seems 
plausible, since it would represent the easiest way of an interaction between the metabolites 
discovered in blood circulation and peripheral cells (Giusepponi et al. 2017). However, the 
accumulation of α-T-13’-COOH in peritoneal leukocytes of α-TOH fed mice is contradictory to 
an exclusive signaling via surface receptors (Pein et al. 2018). Interestingly, α-T-13’-COOH was 
the only LCM accumulating in these cells, although increased blood concentrations of α-T-11’-
COOH and α-T-9’-COOH were detected (Pein et al. 2018). Thus, the selective uptake of α-T-
13’-COOH provides evidence for the existence of a specific transport/uptake system, 
indicating that α-T-13’-COOH must get inside the cell to mediate its regulatory effects. Second, 
the LCMs could serve as ligands for nuclear or cytosolic receptors that potentially mediate 
their gene regulatory functions, as it was already described for the metabolites of vitamins A 
(Perlmann und Jansson 1995) and D (Pike und Meyer 2010). Third, the regulatory functions of 
the LCMs could be mediated by a combination of downstream signaling pathways from 
extracellular and intracellular receptors. The following selection of potential signaling 
pathways mediating regulatory effects of α-T-13’-COOH are predominantly based on current 
findings of our group (including unpublished data). It should be noted that the mentioned 
signaling pathways are only suggestions, which need to be carefully validated by further 
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experiments. Nevertheless, the provided information could serve as a useful starting point for 
future investigations on LCM signaling. 
8.2.4.1 The mitogen-activated protein kinase pathway 
 The mitogen-activated protein kinase (MAPK) pathway, with its central enzymes extracellular 
signal-regulated kinase (ERK)1/2, mitogen-activated protein kinase p38 (p38) and c-Jun N-
terminal kinase (JNK), represents a signaling cascade that is able to transmit an extracellular 
signal to the nucleus. Within this cascade, the extracellular signals are translated into gene 
regulatory signals, enabling a quick and efficient cellular response to various stimuli (Soares-
Silva et al. 2016). The cascade is initiated by the binding of a distinct signaling molecule to a 
surface receptor that is linked to the small G protein rat sarcoma (Ras). After binding of the 
signaling molecule, Ras is activated by a conformational switch of its active site, which in turn 
leads to the subsequent activation of rapidly accelerated fibrosarcoma (Raf). After these initial 
events, the catalytically inactive MAPKs, i.e. ERK1/2, p38 and JNK are activated by multiple 
phosphorylation events, enabling transcriptional regulation of various target genes (Soares-
Silva et al. 2016). Experiments of our group revealed that α-T-13’-COOH leads to an increased 
phosphorylation of ERK1/2 and p38 in murine RAW264.7 macrophages and human fibroblasts 
already 30 min after compound administration (unpublished data). Interestingly, α-T-13-
COOH treatment also increased the expression of dual specificity protein phosphatase 1 
(Dusp1) – an enzymes that deactivates MAPKs by dephosphorylation (Escudero et al. 2019) –  
at later time points (unpublished data). Although there is currently no proof that blockage or 
activation of the MAPK pathway affects the expression of genes regulated by α-T-13’-COOH, 
the results mentioned above provide evidence that the regulatory functions of the metabolite 
could be at least in parts mediated by the MAPK pathway.  
8.2.4.2 The nuclear factor 'kappa-light-chain-enhancer' of activated B-cells pathway 
The transcription factor nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-
кB) is a key regulator of the cellular response against stress, including cytokines, free radicals, 
heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens (Bhatt und 
Ghosh 2014). Under basal conditions, NF-кB remains at its inactive state, i.e. bound to the 
inhibitor of κB (IкB). The IкB protein prevents translocation of NF-кB to the nucleus by masking 
its nuclear localization signals. Due to the stimulation of different surface receptors, such as 
toll-like receptors, NF-кB is among others activated via signal-induced degradation of IкB 
proteins by IкB kinases. After the removal of IкB, the NF-кB subunit p65 is able to enter the 
nucleus where it induces the expression of specific target genes (Bhatt und Ghosh 2014). 
Experiments of our group showed that α-T-13’-COOH itself induced the expression of NF-кB 
target genes. In turn, pre-treatment with α-T-13’-COOH damped the cellular response against 
LPS, probably because of an adaptive response against the initial α-T-13’-COOH stimulus 
(unpublished data). Further, the initiation of an adaptive response against α-T-13’-COOH was 
partially prevented by treatment with a specific inhibitor against the translocation of the p65 
subunit (unpublished data). These data indicates that especially the anti-inflammatory effects 
of α-T-13’-COOH are potentially mediated via the NF-кB pathway. 
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8.2.4.3 Ion channel mediated signaling pathways 
The transmission of extracellular signals via voltage- or ligand-gated calcium channels 
represents another possibility to mediate intracellular processes. Inflowing Ca2+ 
predominantly  exerts regulatory effects on different enzymes by serving as an important co-
factor for their activity (Ahvazi et al. 2003; Lee et al. 2007). Nevertheless, gene regulatory 
effects of Ca2+ have also been described (Barbado et al. 2009; West et al. 2001). Experiments 
of our group showed that the blockage of L-type calcium channels by nifedipine – a well-
investigated Ca2+ channel blocker – reduced the inhibitory effect of α-T-13’-COOH on ABCA1 
mRNA and protein expression (unpublished data). These results were further confirmed by 
the use of BAPTA-AM, a Ca2+ chelator that was specifically designed to act inside the cell. 
Hence, interception of the inflowing Ca2+ and the already present Ca2+ inside the cell also 
reduced the inhibitory effect of α-T-13’-COOH on ABCA1 expression (unpublished data). In 
addition, inhibition of calpain – a calcium dependent enzyme responsible for the degradation 
of ABCA1 – reduced the inhibitory effect of α-T-13’-COOH on ABCA1 protein expression. 
Overall, α-T-13’-COOH could potentially induce Ca2+ inflow via interaction with membrane 
associated calcium channels, leading to transcriptional and post-translational regulation of 
various targets. However, the involvement of Ca2+ in the regulatory function of α-T-13’-COOH 
needs further confirmation, since only one target protein (ABCA1) was studied so far. 
8.2.4.4 Peroxisome proliferator-activated receptor mediated signaling 
The PPARs, i.e. PPARα, PPARβ/δ and PPARγ, predominantly act as sensors for fatty acids and 
fatty acid-derived metabolites and can therefore be activated by a variety of molecules 
(Lefebvre et al. 2006; Neels und Grimaldi 2014; Tontonoz et al. 1998). Based on their function 
as transcription factors, PPARs are able to regulate the expression of different genes involved 
in lipid metabolism, inflammation, proliferation and differentiation (Varga et al. 2011). The 
most common model for PPAR-dependent gene regulation includes the direct transcriptional 
regulation by heterodimerization of a PPAR isoform with the retinoid X receptor (RXR). Under 
basal conditions, the heterodimer is bound to the so-called PPAR response element in the 
promoter region of target genes as well as to a corepressor complex preventing transcription. 
Upon ligand binding, the corepressor complex is replaced by coactivators, resulting in the 
transcription of target genes (Varga et al. 2011). Based on their structural similarities to 
unsaturated fatty acids, i.e. natural ligands of the different PPAR forms, the vitamin E LCMs 
were also suggested as potential PPAR ligands. Hence, the α-T-13’-COOH dependent 
regulation of the PPAR target gene Angptl4 was extensively studied in THP-1 macrophages 
(manuscript I). Since PPARδ represents the predominant PPAR form in human THP-1 
macrophages (Vosper et al. 2001), the chemical PPARδ antagonist GSK3787 was used to 
investigate whether PPARδ was involved in the induction of ANGPTL4 mRNA expression by α-
T-13’-COOH. Indeed, co-incubation of α-T-13’-COOH and GSK3787 significantly reduced the 
induction of Angptl4 expression, indicating that the gene regulatory function of α-T-13’-COOH 
is probably mediated by PPARs. This concept seems plausible, since other studies also 
observed α-T-13’-COOH induced induction of PPAR target genes, such as Plin2 and Cd36 
(Wallert et al., 2014b; Schmölz et al., 2018). Although inhibition of PPARδ had no effect on 
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functional study parameters, these results provide nonetheless evidence that the regulatory 
functions of α-T-13’-COOH could be at least in part mediated by PPARs.  
8.2.4.5 Pregnane-X-receptor mediated signaling 
The pregnane-X-receptor represents another nuclear receptor with a proven association to α-
T-13’-COOH mediated gene expression. Transcriptional regulation via PXR is accomplished by 
the same mechanisms described for the PPARs, i.e. dimerization with RXR and subsequent 
activation of target gene transcription via ligand binding. Using a reporter gene assay, Podszun 
et al. showed that α-T-13’-COOH was able to induce PXR activity. For further verification, the 
expression of PXR target genes was investigated in human epithelial-like colon LS180 cells 
after α-T-13’-COOH treatment. In line with the results of the reporter gene assay, P-gp protein 
expression was also induced by α-T-13’-COOH (Podszun et al. 2017). In addition, δ-TE-13’-
COOH (i.e. GA) was also proposed as a selective PXR agonist (Bartolini et al. 2020). With PXR, 
another nuclear receptor is probably involved in the regulatory functions of vitamin E-derived 
LCMs, making it more and more likely that these molecules could serve as ligands for nuclear 
receptors. 
8.3 Future perspectives of LCM research 
After a decade of research on the vitamin E-derived LCMs, their exact mode of action as well 
as their significance for human health are still far from being unveiled.  
 
Figure 9: Schematic overview on major aims of future LCM research. LCM (long-chain 
metabolite) 
However, in vitro studies discovered a variety of biological functions of the LCMs (Schubert et 
al. 2018) that were supplemented by initial findings from in vivo trials, such as the appearance 
of LCMs in human blood (Wallert et al. 2014b) or the selective accumulation of α-T-13’-COOH 
in murine peritoneal leukocytes (Pein et al. 2018). Altogether, these studies contributed to the 
generation of fundamental hypotheses in the field: (i) The LCMs possess a physiologically 
relevance for the human body; (i) The LCMs represent functional and therefore active forms 
of their vitamin precursors; (iii) Essentiality of vitamin E for human health is closely linked to 
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the LCMs (Galli et al. 2017). As mentioned before, these hypotheses are predominantly based 
on in vitro data that requires careful validation in animal models and humans to change the 
current picture of vitamin E-derived LCMs as a ‘highly speculative area’ of vitamin E research. 
Thus, it seems unavoidable for the scientific progress in the field to switch the focus from in 
vitro to in vivo models and human trials. Findings from these ‘next generation’ studies and 
trials could generate useful information on the essentiality of vitamin E and it’s LCMs for 
human health as well as on potential clinical benefits of these molecules. The following section 
will discuss ideas for future in vitro-, in vivo model based- and human investigations on vitamin 
E LCMs, which I personally consider as major tasks for the next decade of LCM research. A 
short summary of the from my point of view most important aims of future LCM research is 
provided in Figure 9. However, the crucial prerequisite for this is to overcome the limitations 
mentioned in the Section 8.2 “Limitations of current LCM research”.  
8.3.1 In vitro studies 
Although in vitro models proved their value as an easy accessible, easy to handle and reliable 
tool for the initial characterization of LCM functions, current research issues concerning 
physiologic aspects revealed the limitation of these experimental models. Nevertheless, cell 
culture based studies will still be of interest for future investigations on the general modes of 
action of the vitamin E-derived LCMs. This includes the elucidation of signaling pathways that 
mediate LCM functions as well as the identification of proteins involved in their cellular 
uptake. Here, target-fishing experiments, i.e. incubation of immobilized LCMs with cell lysates, 
could serve as a useful tool for the elucidation of specific LCM-protein interactions. After their 
separation by 2D gel electrophoresis, the proteins could be isolated and analyzed via MS to 
identify potential receptors or transporters of the LCMs. In addition, target-fishing 
experiments should be supplemented by the selective knockdown or overexpression of key 
enzymes in central signaling cascades as well as by the use of selective chemical inhibitors or 
activators against signaling proteins. The combination of both methods could potentially 
enable the identification of fundamental modes of actions in LCM signaling. 
8.3.2 In vivo studies based on animal models  
A recent investigation of Pein et al. provided a first impression of the great potential of animal 
models for future LCM research (Pein et al. 2018). In general, animal models could be used for 
all kinds of investigations that cannot be carried out in humans or with human material (for 
ethical reasons). From my personal point of view, future animal studies should therefore 
predominantly focus on the elucidation of the currently unknown LCM physiology. This 
includes regulation of vitamin E metabolism, transport mechanisms for vitamin E-derived 
LCMs in the body, distribution and uptake kinetics of the LCMs in extrahepatic tissues, 
identification of physiologically relevant forms of vitamin E LCMs as well as their stability 
against xenobiotic degradation. To accomplish these complex objectives, different methodical 
approaches are conceivable. 
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8.3.2.1 Investigation of hepatic metabolism 
Since the hepatic metabolism of vitamin E in humans and rodents appeared to be very similar 
(Wallert 2014a), Cyp4f14 (= CYP4F2) or Cyp3a11 (= CYP3A4) knockout mice, i.e. rate limiting 
enzymes of vitamin E catabolism, could serve as suitable models for the investigation of the 
physiologically significance of vitamin E and its LCMs (Bardowell et al. 2012b; van Herwaarden 
et al. 2007). To date, only one study used Cyp4f14-/- mice fed with a soybean oil diet to 
investigate metabolization rates of α-, γ- and δ-TOH. Interestingly, whole-body metabolization 
of γ-TOH was reduced by 90% but only by 68% for α- and δ-TOH (Bardowell et al. 2012b). The 
authors concluded that although Cyp4f14 seems to be the major vitamin E ω-hydroxylase in 
mice, other CYPs, such as Cyp3a11 are also important for vitamin E metabolism. However, 
there are currently no studies available using Cyp3a11-/- mice in association with vitamin E, 
which could therefore represent a starting point for future investigations. Unfortunately, 
Cyp4f14/Cyp3a11 double knockout mice – an animal model with a likely completely 
eliminated vitamin E metabolism – are not commercially available because they are probably 
not viable. Beside the use of knockout models, co-administration of vitamin E and sesamin, 
i.e. an inhibitor of Cyp4f14/Cyp3a11 (= CYP4F2/CYP3A4) dependent ω-hydroxylation (Sontag 
und Parker 2002), represents another approach for the investigation of vitamin E metabolism 
in rodent models. This method was successfully applied by Pein et al. to investigate α-T-13’-
COOH, α-T-11’-COOH and α-T-9’-COOH concentrations in murine plasma and exudates (Pein 
et al. 2018). Based on their promising results, the use of sesamin could also be considered for 
future in vivo studies on vitamin E metabolism.  
8.3.2.2 Tissue distribution 
UPLC-MS/MS based analysis of vitamin E-derived LCM concentrations in blood, exudates and 
cells from α-TOH fed mice was approved as a reliable approach for the investigation of LCM 
distribution in vivo (Pein et al. 2018). In addition, Raman spectroscopic analysis together with 
the administration of deuterated LCMs or deuterated forms of their vitamin precursors could 
represents another promising tool for the identification of LCM distribution patterns in various 
tissues (Stiebing et al. 2017). Unfortunately, the use of deuterated compounds is expensive 
and therefore likely not practicable for large animal studies.  
8.3.2.3 Pharmacokinetics 
To elucidate pharmacokinetics of LCM metabolism, rodents could be treated with defined 
doses of deuterated vitamin E to enable the selective determination of newly formed 
metabolites (Traber et al. 2017). Afterwards, blood and tissues samples could be withdrawn 
from the animal at different time points to determine LCM concentrations in blood and 
tissues. The generated data will provide useful information on suitable dosages for future in 
vivo experiments as well as enable to estimate how fast the LCMs arrive at their potential sites 
of action.  
8.3.2.4 LCM stability 
Information about the stability against xenobiotic degradation are of special interest for in 
vivo studies that includes direct administration of the LCMs. The study of Pein et al. provided 
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first evidence for a minor degradation of α-T-13’-COOH in mice after intraperitoneal injection 
of the compound. Hence, α-T-13’-COOH concentration in plasma and exudates remained on 
a constant level after its initial increase due to compound injection. In contrast, δ-TE-13’-
COOH concentrations in plasma and exudates did not increase after intraperitoneal injection 
of the compound, indicating that δ-TE-13’-COOH is immediately degraded by xenobiotic 
metabolism (Pein et al. 2018). This finding is further strengthened by the results of manuscript 
IV, where weekly injection of δ-TE-13-COOH had no influence on inflammatory processes in 
atherosclerotic mice, potentially because of the rapid degradation of the compound (Wallert 
et al. 2019). To deepen the knowledge on this issue, comparable studies should be carried out 
for all LCM forms. In addition, chemically modified LCMs, i.e. inaccessible for degradation via 
β-oxidation due to the replacement of single hydrogen atoms by fluorine atoms (suggested by 
Prof. Dr. Marc Birringer), could be used as a further reference for these experiments.  
8.3.2.5 Identification of physiological relevant forms of vitamin E LCM  
The investigation of Pein et al. showed that α-T-13’-COOH selectively accumulated in 
peritoneal leukocytes of mice that where fed α-TOH enriched diets. In contrast, other α-LCMs, 
such as α-T-11’-COOH and α-T-9’-COOH, were not detected (Pein et al. 2018). On the one 
hand, these results provide further evidence for the physiological significance of the vitamin 
E-derived LCMs, at least for α-T-13’-COOH, but on the other hand they raise a new question 
whether there are differences between the physiological relevance of the different LCM 
forms. To address this question, comparable in vivo studies based on a-, β-, γ-, and δ-TOH as 
well as a-, β-, γ-, and δ-TE enriched diets should be carried out, using an extended analytical 
spectrum of potential target tissues and cells. Especially the comparison of the physiologically 
relevance of α-TOH metabolites (considered the most important form of vitamin E in humans 
(Azzi 2019)) and γ-TOH metabolites (most relevant form for human nutrition in the USA (Péter 
et al. 2019)) could be of interest.  
Beside their use for the elucidation of physiological fundamentals, animal models could also 
be used for a more targeted characterization of disease relevant functions and applications of 
the LCMs, as it was already done for atherosclerosis and immune function (Wallert et al. 2019; 
Pein et al. 2018).   
8.3.3 Human studies 
From my personal point of view, the implementation of investigations on physiologic 
fundamentals of vitamin E-derived LCMs in humans will be difficult in the nearby future. As 
already explained, these kind of investigations should initially be limited to animal models for 
ethical reasons (extraction of tissue samples, administration of deuterated compounds, 
inhibition of metabolic pathways), reasons of inter-individual variation (higher variation within 
humans compared with cultured laboratory animals) and handling reasons. Although the 
transferability of data from animal models to humans is not completely possible, the findings 
in animals can reveal first insights into LCM physiology that can be expanded by smaller 
studies on selected aspects of human LCM physiology, using tissue samples from biopsies or 
surgeries. However, the next decade of LCM research in humans should rather be focused on 
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the systematic collection and investigation of blood samples. To maximize the knowledge 
outcome from this easy accessible study material, LCM concentrations and distribution 
patterns should be analyzed in blood samples of healthy volunteers and patients with various 
types of non-communicable diseases. The collected data would potentially provide useful 
information on particularities of LCM concentrations or distribution ratios among their 
different forms in non-communicable diseases. This seems to be even more important, since 
recent studies indicated potential health benefits of vitamin E supplementation in 
cardiovascular diseases (Wiener et al. 2019), diabetes (Hodis und Mack 2019), metabolic 
syndrome (Bruno 2019), nonalcoholic fatty liver disease (NAFLD) (Banini und Sanyal 2019), 
asthmatic disease (Cook-Mills 2019) and Alzheimer’s disease (Eckert 2019). Thus, the collected 
data could be used for specific applications, such as personalized vitamin E therapies. The 
potential use of personalized vitamin E administration was already indicated by large-scale 
human trails at the beginning of the 21th century. In general, these studies failed to provide 
clear evidence for health-promoting effects of vitamin E supplementation in the secondary 
prevention of cardiovascular diseases in a broad study population (Wiener et al. 2019). 
Interestingly, health promoting effects of vitamin E were only limited to certain parts of the 
overall study population (Lodge 2019). The reason for these individual differences were later 
identified in the pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS) trial. In 
this study, supplementation with 800 IU all-rac-α-TOH acetate for 96 days improved the 
hepatic histology of non-alcoholic steatohepatitis patients. However, not all patients of the α-
TOH intervention group showed the same grade of histological improvement. Thus, Cheng et 
al. used fifteen subjects that either responded or did not respond to vitamin E 
supplementation (based on a decrease in NAFLD score) for additional metabolomics profiling. 
Indeed, a number of metabolites could be classified as biomarkers of vitamin E response 
(Cheng et al. 2012). Unfortunately, the analysis of Cheng et al. as well as further studies on 
biomarkers for vitamin E responders and non-responders did not consider the vitamin E-
derived LCMs (Da Costa et al. 2013; West et al. 2015; Cole et al. 2013). Hence, current 
metabolomics approaches should be expanded by the determination of vitamin E-derived 
LCMs to prove their suitability as new potential biomarkers of the vitamin E effect on NAFLD. 
If the concept holds true and LCMs, such as α-T-13’-COOH, represent the biologically active 
forms of vitamin E as well as reliable biomarkers for the vitamin E effect on NAFLD in humans, 
determination of vitamin E-derived LCMs in blood could help to identify suitable patients for 
personalized and cost-efficient vitamin E therapies (Lodge 2019; Nuijten 2019).  
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9 Summary 
With only two years away from the 100th anniversary of the discovery of vitamin E as an 
essential nutrient in 1922, we have still more questions than answers concerning its 
significance for human health. During the past hundred years, vitamin E research was 
characterized by great hopes but also bitter disappointments, which finally led to a strong 
decline of interest in this research area. However, vitamin E research is currently experiencing 
a scientific ‘renaissance’, which is among others attributed to the unrevealing of vitamin E 
metabolism in humans and to the elucidation of biological functions of the newly formed 
metabolites. Since their initial determination in human serum, especially the long-chain 
metabolites (LCMs), i.e. the first metabolites formed during the hepatic degradation of vitamin 
E, appeared as a class of molecules with putative relevance in the human body. Driven by a 
small community of ambitious scientist, research on these compounds has made great 
progress over the last decade, leading to the establishment of the LCMs as an acknowledged 
area of vitamin E research.  
As one of the founding members of the LCM community, the work of our group is 
predominantly focused on the advance of this new and promising field of vitamin E research. 
Hence, the ten manuscripts included in this thesis also contribute to the progress of key areas 
in the field of LCM research, i.e. elucidation of biological functions, identification of signaling 
pathways and the comparison of LCM functionality with their vitamin precursors. The main 
contributions of the included research articles to the progress of LCM research can be 
summarized as follows:  
(i)  Discovery of hitherto unknown functions of the LCMs in inflammation and cellular lipid 
metabolism, i.e. inhibition of nitric oxide and prostaglandin formation, modulation of 
cellular lipid uptake and storage as well as prevention of VLDL-mediated foam cell 
formation.  
(ii)  Development of a new methodical approach for the investigation of LCM-mediated 
effects on lipoprotein lipase activity. 
(iii)  First description of a causal connection between gene regulatory effects of α-tocopherol-
derived 13’-carboxychromanol (α-T-13’-COOH) and the peroxisome proliferator-activated 
receptor δ.  
(iv)  Description of differences concerning potency and function of α-tocopherol and α-T-13’-
COOH on two hitherto unknown aspects of the cellular lipid homeostasis, i.e. regulation 
of PLIN2 expression and ANGPTL4-dependent regulation of LPL activity.  
(v)  Generation of indications for an atheroprotective potential of α-T-13’-COOH.  
Despite of this great progress on fundamental areas of LCM functionality, their exact modes 
of action as well as their significance for human health are still a puzzle waiting to be solved. 
Especially the lack of data on LCM physiology in a living organism represent a great limitation 
of current and the major challenge of future investigations. Nevertheless, the already existing 
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studies on vitamin E-derived LCMs (including the manuscripts I to X) enabled the generation 
of major working hypotheses for future LCM research:  
(i)  The LCMs have a physiological relevance for human physiology and health. 
(ii)  The LCMs represent functional and therefore active forms of their vitamin precursors. 
(iii)  Essentiality of vitamin E for human health is closely linked to the LCMs. 
However, further studies are required to finally confirm these hypotheses. 
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10 Zusammenfassung 
Zwei Jahre vor dem 100. Jahrestag der Entdeckung von Vitamin E als essentiellen Nährstoff im 
Jahr 1922 gibt es immer noch viele ungeklärte Fragen hinsichtlich der Bedeutung des Vitamins 
für die menschliche Gesundheit. Die Vitamin-E-Forschung der letzten 100 Jahre war 
diesbezüglich von großen Hoffnung, aber auch herben Enttäuschung geprägt, die letztlich zu 
einem starken Interessenrückgang an diesem Forschungsbereich geführt haben. Derzeit 
erlebt die Vitamin-E-Forschung allerdings eine Renaissance, was unter anderem auf die 
Entdeckung des Metabolismus von Vitamin E sowie auf die Aufklärung von biologischen 
Funktionen der neu gebildeten Metaboliten zurückzuführen ist. Seit dem initialen Nachweis 
der langkettigen Metaboliten von Vitamin E (LCMs) (den ersten Metaboliten die während des 
Abbaus von Vitamin E in der Leber gebildet werden) im humanen Serum wird dieser 
Stoffklasse eine vermeintliche Relevanz für den menschlichen Körper nachgesagt. 
Angetrieben von einer kleinen Gemeinschaft ambitionierter Wissenschaftler hat die 
Forschung an diesen Verbindungen in den letzten zehn Jahren große Fortschritte erzielt und 
zur Etablierung der LCMs als anerkanntes Gebiet innerhalb der Vitamin-E-Forschung geführt.  
Als eines der Gründungsmitglieder der „LCM Community“ konzentriert sich die Arbeit unserer 
Gruppe vorwiegend auf das Vorantreiben dieses neuen und vielversprechenden 
Forschungsbereiches. Auch die zehn in dieser Arbeit enthaltenen Manuskripte tragen dabei 
wesentlich zum wissenschaftlichen Fortschritt in Schlüsselbereichen auf dem Gebiet der LCM-
Forschung bei. Diese umfassen unter anderem die Aufklärung biologischer Funktionen, die 
Identifizierung von Signalwegen und den funktionellen Vergleich der LCMs mit ihren 
Vitaminvorstufen. Die genauen Beiträge der in dieser Dissertation enthaltenen 
Forschungsartikel zum wissenschaftlichen Fortschritt auf dem Gebiet der LCM-Forschung 
lassen sich wie folgt zusammenfassen: 
(i)  Die Entdeckung bisher unbekannter Funktionen der LCMs bei Entzündungsprozessen und 
innerhalb des zellulären Lipidstoffwechsels, d.h. die Hemmung der Stickstoffmonoxid- 
und Prostaglandin Produktion, die Modulation der zellulären Lipidaufnahme und 
Lipidspeicherung, sowie einer Schutzfunktion vor VLDL-vermittelter Schaumzellbildung.  
(ii) Die Entwicklung eines neuen methodischen Ansatzes zur Untersuchung von LCM-
vermittelten Effekten auf die Lipoproteinlipase-Aktivität. 
(iii)  Die erste Beschreibung eines kausalen Zusammenhangs zwischen der genregulatorischen 
Wirkung von α-Tocopherol-abgeleitetem-α-13'-Carboxychromanol (α-T-13'-COOH) und 
dem Peroxisom-Proliferator-aktivierten Rezeptor δ. 
(iv)  Beschreibung von Unterschieden hinsichtlich Wirksamkeit und Funktion von α-
Tocopherol und α-T-13'-COOH in Bezug auf zwei bisher unbekannte Aspekte der 
zellulären Lipidhomöostase, d.h. der Regulation der Expression von Adipophilin und der 
Angiopoietin-like 4 abhängigen Regulation der Aktivität der Lipoproteinlipase. 
(v)  Die Generierung von Hinweisen auf ein atheroprotektives Potential von α-T-13'-COOH.  
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Trotz dieser großen Fortschritte in grundlegenden Bereichen der LCM-Funktionalität sind ihre 
genauen Wirkmechanismen sowie ihre Bedeutung für die menschliche Gesundheit immer 
noch unklar. Insbesondere die fehlenden Daten zur Physiologie der LCMs im lebenden 
Organismus stellen einen großen Mangel aktueller und die größte Herausforderung für 
zukünftige Untersuchungen dar. Jedoch ermöglichen die bereits vorhandenen Studien zu den 
aus Vitamin E gebildeten LCMs (einschließlich der Manuskripte I bis X) die Generierung von 
wichtigen Arbeitshypothesen für die zukünftige Forschung auf diesem Gebiet:  
(i)  Die LCMs sind von physiologischer Relevanz für den menschlichen Körper.  
(ii)  Die LCMs stellen funktionelle und daher aktive Formen ihrer Vitaminvorläufer dar. 
(iii)  Die Relevanz von Vitamin E für die menschliche Gesundheit ist eng mit den LCMs 
verbunden. 
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